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Objective: This study examined potential differences between patients in outpatient 
treatment for substance use disorders with ADHD and those without ADHD. Previous research 
has indicated that there is a higher prevalence of ADHD among patients within substance abuse 
treatment settings than the general population, but there is little research that describes how 
individuals with this comorbidity might differ. We were interested in determining potential 
differences between these groups in the areas of substance use history, drinking motives, and 
executive functioning which might influence the treatment of substance use disorders.    
Method: A total of 23 participants (mean 25.5 years) from a local substance use treatment 
facility qualified for the study based on the results of a prescreening to determine if they had 
symptoms of ADHD in childhood (WURS-25) and adulthood (ASRS). Thirteen patients met 
diagnostic criteria (CIDI interview) for both current and childhood symptoms of ADHD with 10 
additional patients serving as a comparison group reporting neither childhood nor current 
symptoms of ADHD. Participants completed assessments regarding their substance use history, 
drinking motives and a measure of executive functioning (BDEFS); the comorbid ADHD and 
substance use group additionally completed several qualitative questions regarding how ADHD 
has influenced their efforts at treatment and recovery. Results: Participants with comorbid 
ADHD and substance use disorders were clearly a distinct subgroup; they had a different profile 
 for substance use history, including using more overall types of substances as well as cocaine 
and prescription stimulants; were more likely than those with substance use alone to initiate 
alcohol, nicotine, and marijuana at an earlier age; and had used alcohol for a longer period of 
time. Motives for drinking did not differ although the ADHD group had somewhat more conduct 
problems in childhood. Both groups reported significant difficulties with executive functioning, 
but those with comorbid ADHD and substance use disorders reported significantly more 
problems with executive functioning in daily life than those without ADHD. Although the 
number of past treatment episodes did not differ, qualitative responses suggested ways ADHD 
might impact treatment. Conclusion: More research is needed to better characterize comorbid 
ADHD and substance use disorder and determine the implications such differences might have 
on treatment and recovery efforts.  
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CHAPTER 1: LITERATURE REVIEW 
Comorbid mental health conditions accompanying substance use disorders negatively 
influence risk, onset, course, severity, and treatment of the substance abuse. One of the most 
common comorbidities associated with substance use disorders is Attention Deficit Hyperactivity 
Disorder (ADHD), a disorder marked by deficits in attention and executive functioning. A recent 
meta-analysis reviewed 29 studies that looked at the prevalence rates of ADHD within substance 
abuse populations and found that prevalence of ADHD was 21% in adults and 25% among 
adolescent populations (van Emmerik-van Oortmerssen et al., 2012). This is highly significant 
because the prevalence rate of ADHD within the general population is typically only 3-5% 
(Barkley, Murphy, & Fischer, 2008). However, for many of these patients, ADHD may go 
unrecognized (Kessler et al., 2006); although they may meet the criteria for a diagnosis of 
ADHD, they may not have been previously diagnosed before entering substance abuse treatment.  
Having ADHD may negatively influence the success of a patient’s substance abuse 
treatment, as people with ADHD may struggle with poorer treatment adherence, difficulty with 
achieving the goals set in treatment, and higher rates of relapse upon leaving substance abuse 
treatment due to attentional difficulties and poor executive functioning associated with the 
disorder (Arias et al, 2008; Carroll & Rounseville, 1993; Ohlemeier et al., 2008; & Wise, Cuffe, 
& Fischer, 2001). For example, one study that looked at patients entering a hospital-based clinic 
for methadone treatment found that 19% of the sample had self-reported symptoms of ADHD 
that interfered with their life functioning (Kolpe & Carlson, 2007). These patients had more 
difficulty maintaining abstinence 9-months later than their peers that did not struggle with these 
symptoms (Kolpe & Carlson, 2007). This pattern could be due to impulsivity, missing 
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appointments due to poor planning, or other factors associated with their ADHD symptoms. It is 
possible that these outcomes could be compounded when ADHD is undiagnosed and untreated.   
The identification of these patients and the eventual development of evidence-based 
psychosocial treatments for ADHD within substance use populations could greatly improve the 
course and success of their treatment. This paper will first review relevant background literature 
on substance use disorders, ADHD and their co-occurrence, with a particular focus on reasons 
for their association and the likely impact of ADHD on substance use pattern and recovery.  
Second, a proposed thesis project is described which examines the association of co-occurring 
ADHD in substance abuse patients on both substance abuse variables and reported problems in 
executive functioning.  
Substance Use Disorders  
  According to data from the National Survey on Drug Use and Health, an estimated 20.6 
million persons (8.0 percent of the population aged 12 or older) were classified with substance 
abuse or dependence in the past year based on the DSM-IV criteria (SAMHSA, 2012).  Of these, 
2.6 million were classified with abuse or dependence for alcohol as well as illicit drugs, 3.9 
million had abuse or dependence of illicit drugs but not alcohol, and 14.1 million had abuse or 
dependence on alcohol but not illicit drugs (SAMHSA, 2012). It is estimated that 22.5 million 
Americans aged 12 or over—8.7% of that age group—reported using an illicit drug within a 
month of being interviewed in 2011. These included but were not limited to marijuana, cocaine, 
heroin, hallucinogens, inhalants, and non-medically used prescription drugs.  The National 
Institute on Drug Abuse (2005) reports that substance abuse is a serious public health, social, and 
economic problem. The National Institute on Alcohol Abuse and Alcoholism reports that the 
annual cost related to the misuse of alcohol to be over $180 billion, and combination of alcohol, 
 3 
 
tobacco, and illicit drug use to be over $450 billion annually (National Institute on Drug Abuse, 
2005).  
The previous Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) 
(American Psychiatric Association, 2000) divided substance related disorders into two 
categories: substance use disorders and substance-induced disorders. For the purpose of this 
research, substance use disorders including substance abuse and substance dependence were 
reviewed. The hallmark of substance dependence is a maladaptive pattern of substance use that 
continues for at least 12 months, with three or more cognitive, behavioral, and/or psychological 
symptoms (American Psychiatric Association, 2000). These symptoms include tolerance, 
withdrawal, and several indicators of compulsive use reflective of dependence. Tolerance means 
that increased amounts of the substance are needed to achieve the same effect, and withdrawal 
refers to the physiological substance-specific syndrome that occurs when one refrains from use 
of the substance after a long period of heavy use (American Psychiatric Association, 2000).The 
criteria for compulsive use can be met in several ways including failure to meet important social 
or occupational obligations, time spent in the activities necessary to obtain the substance, 
persistent or unsuccessful efforts to cut down or control substance use, and taking the substance 
in larger amounts or over a longer period than was intended.  
In order for an individual to meet the criteria for substance abuse, there must be evidence 
of persistent problems(s) in at least one of the following areas; vocational or school, problems 
with the legal system, social and/or interpersonal problems, and physically hazardous situations 
(American Psychiatric Association, 2000).  
The historic distinction between substance abuse and substance dependence suggests that 
substance abuse is a less severe disorder or a precursor to substance dependence. However, 
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according to the literature, the distinction between the two has been increasingly questioned on 
both psychometric and conceptual grounds (Verges, Steinley, Trull & Sher, 2010). Some have 
suggested that these are not in fact distinct categories but a unidimensional continuum of 
substance-problem severity (Hasin, Hatzenbuehler, Keyes, & Ogburn, 2006; Martin, Chung, & 
Langerbucher, 2008). In fact, the most recent version of the Diagnostic and Statistical Manual 
(DSM-5) has done exactly that. They have combined substance abuse and substance dependence 
criteria into one category called “substance use disorder” with the understanding that diagnosis is 
to be made if individuals continue to use the substance despite substance-related problems 
(American Psychiatric Association, 2013). Severity specifiers are based on the number of 
specific substance symptom criteria that are endorsed, with mild indicating two or three 
symptoms, to severe indicating six or more of 11 possible symptom criteria (American 
Psychiatric Association, 2013).   
Substance abuse is properly thought of as a developmental disorder in that onset typically 
begins in adolescence with the prevalence of alcohol and other drug use and associated problems 
peaking in young adulthood (Hingson, Heeren, & Winter, 2006; Rohde, Lewinsohn, Kahler, 
Seeley, & Brown, 2001).  For instance, alcohol use is most likely to become problematic in late 
adolescence and early to mid-twenties, and most individuals who develop alcohol-related 
disorders will do so by their late 30’s (American Psychiatric Association, 2013). Research 
suggests that those who start drinking before age 14 are more likely to develop alcohol 
dependence when compared to those that start drinking at age 21 (Hingson et al., 2006). In 
addition, adolescents who have problematic use of alcohol are more likely to develop alcohol 
dependence and other substance use disorders, compared to those without alcohol use disorders 
in adolescence, suggesting that earlier problematic use does not necessarily resolve without 
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intervention (Rohde et al., 2001).   For these reasons, early identification and developing 
effective interventions in young adults at risk are particularly important. One such known risk 
factor is ADHD especially when associated with conduct difficulties. 
Attention Deficit Hyperactivity Disorder 
ADHD has been defined as a common, highly heritable, neurobehavioral disorder, 
beginning in childhood but often persisting into adulthood, which is associated with significant 
impairment in psychosocial functioning (Biederman, 2005). This definition provides a useful 
framework for discussing the diagnosis of ADHD, as it includes some of the components 
important to the diagnosis such as age of onset, and impairment in life functioning. According to 
the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), “The 
essential feature of Attention-Deficit/Hyperactivity Disorder is a persistent pattern of inattention 
and/ or hyperactivity-impulsivity that interferes with functioning or development”  (2013, p. 61). 
Individuals diagnosed with ADHD are thought to fall into one of three presentation types based 
on the prevalence of their symptoms: predominately inattentive, predominately hyperactive-
impulsive, or combined inattentive/ hyperactive-impulsive. However useful these presentation 
types may be for clinical use, research suggests that they do not demonstrate stability over time, 
and thus classification based on these presentation types as distinct forms of the disorder may not 
be justified through the lifespan (Willcutt et al., 2012).  
ADHD is a disorder that was historically associated with childhood (Barkley et al., 2008). 
However, ADHD has been shown to be relatively persistent across the lifespan, and adult ADHD 
has been generating more attention and thus more controversy in recent years (Barkley et al., 
2008; Spencer, Biederman, Wilens & Farone, 1994). While ADHD in children was first 
recognized in the early 1900s, understanding about the persistence of this disorder into adulthood 
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was not recognized until the 1970’s (Wood et al., 1976). In fact, adult ADHD may actually be 
under-diagnosed because it has only recently been recognized by the professional community, 
particularly for those with the inattentive subtype (Wells, 2005). Compared with children, 
symptoms in adults are less disruptive, as they tend to reflect the changes in their activities and 
responsibilities (Adler & Cohen, 2004). Thus, diagnosis of ADHD in adults involves careful 
interviewing about the lifelong history of inattention, restlessness, impulsivity, and 
disorganization—rather than hyperactivity which is easier to identify (Faraone, Spencer, 
Montano, & Biederman, 2004). 
According to one prominent theory by Barkley (1997), those with ADHD may have poor 
control over executive functioning which may be linked to deficits in the frontal-lobe regions of 
their brain. The symptoms of ADHD can present in many different ways and symptoms vary 
among diagnosed  individuals: poor organizational skills, inability to attend to details at work or 
school, excessive procrastination, or “hyper-focus” in which an individual focuses on relatively 
unimportant details or tasks to the exclusion of everything else (Elliott, 2002). Adults most 
frequently report the symptoms of ADHD as “feeling scattered and being chronically late for 
appointments, anxious, irritable, and overwhelmed with the tasks of daily living” (Elliott, 2002, 
p. 737). 
According to the DSM-IV, the prevalence of school aged-children with ADHD ranges 
from 4%-12%, but it is suggested that these data may vary based on the population and sampling 
method (American Psychiatric Association, 2000). Additionally, the DSM-IV does not suggest a 
prevalence range for adolescents or adults because data are limited on the persisting prevalence 
of ADHD.  One study suggests the rates for prevalence into adulthood is approximately 50%-
70%, based on data from self-reports and parent reports of childhood functioning (Barkley, 
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Fischer, Smallish, & Fletcher, 2002). This indicates that as many as one-third to one-half of all 
children with ADHD appear to outgrow it, and no longer meet the diagnostic criteria as young 
adults (Barkley et al., 2002). ADHD prevalence into adulthood is thought to be between 1% and 
6% of the general population (Wender, Wolf, & Wasserstein, 2001). One epidemiological study 
rated the prevalence of adult ADHD at 4.4% (Kessler et al., 2006). While the specific statistics 
are not entirely clear, it does appear that for half of those diagnosed in childhood, ADHD will 
persist into adolescence and adulthood. The prevalence of ADHD in adulthood has been difficult 
to establish due to controversies surrounding diagnostic criteria, as well as a relative shortage of 
longitudinal studies that follow children with ADHD into adulthood (Barkley et al., 2008). 
Analysis based on longitudinal studies following children with ADHD into adulthood suggest a 
prevalence rate between 3.3% and 5.3% although "actual studies of large general population 
samples have more recently placed the figure at nearly 5% of adults, representing more than 11 
million adults in the United States alone" (Barkley et al., 2008, pp. 24-25). Differences in 
percentages of adults with ADHD that has persisted since childhood may be reflective of a lack 
of operational definition, rather than the actual course of ADHD (McGough & Barkley, 2004).  
Conduct Difficulties  
In the previous iteration of the DSM (IV-TR), conduct disorder (CD), oppositional 
defiant disorder (ODD), and attention-deficit hyperactivity disorder (ADHD) are presented under 
the grouping of Attention-Deficit and Disruptive Behavior Disorders (American Psychiatric 
Association, 2000). ODD is characterized as “a recurrent pattern of negativistic, defiant, 
disobedient, and hostile behavior directed at authority figures that persists for at least six 
months,”  and frequently manifests in children as defiance of authority, excessive anger and 
resentment, and may include bullying, frequent loss of temper and blaming others (American 
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Psychiatric Association, 2000, p. 100). In order for ODD to be diagnosed, 4 of the 8 symptoms 
must be endorsed, and must cause significant functional problems at home, school, or in social 
relationships (American Psychiatric Association, 2000). If left untreated, as many as 52% of 
children with ODD will continue to meet the diagnosis for ODD three years after initial 
diagnosis, and half of that group will later meet the criteria for conduct disorder. Therefore ODD 
may be considered an antecedent to CD (Lahey, Loeber, Quay, Frick, & Grimm, 1992). There is 
a hierarchical relationship between ODD and CD, which indicates that although they fall along 
the same continuum, CD is a more severe behavioral disorder than ODD, and if CD is diagnosed, 
ODD is not (American Psychiatric Association, 2000). 
The essential feature of CD is “a repetitive and persistent pattern of behavior in which the 
basic rights of others or major age-appropriate societal norms or rules are violated (American 
Psychiatric Association, 2000, p. 93)” CD is a condition that describes an individual with 
aggressive, antisocial, and criminal tendencies. When making a diagnosis of CD, multiple factors 
must be considered including the symptoms, timing of onset, and the function of the symptoms 
(Olsson, 2009). It is also important to consider the complicated interplay of biological and 
environmental factors including cognitive, neurological, intrapersonal factors, social influences, 
and context, as these etiological mechanisms serve as important considerations in which 
evidenced-based treatments are utilized in treating the disorder (Murrihy, Kidman, & Ollendick, 
2010). 
There are two developmental courses of CD: “childhood onset” type when conduct 
disorder symptoms occur before age 10, and “adolescent-onset” type when symptoms occur after 
the age of 10. Diagnosis involves meeting at least three of the criteria over the past twelve 
months, with at least one occurrence within the last six months, and criteria include aggression to 
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people and animals, destruction of property, deceitfulness or theft, or serious violation of the 
rules, which causes significant impairment in multiple domains (American Psychiatric 
Association, 2000). Just as CD in childhood is often preceded by a diagnosis of ODD, CD is 
often considered a precursor to antisocial personality disorder. Not all of those diagnosed with 
CD in childhood or adolescence will receive a diagnosis of antisocial personality disorder as an 
adult; only 25-40% of youth with CD will develop antisocial personality disorder (Loeber, 
Keenan, Lahey, Green, & Thomas, 1993).    
In the presence of substance use disorders, it can be difficult to diagnose conduct 
disorder, as it is challenging to determine which symptoms are related to the influence of alcohol 
or other drugs, and which are truly conduct related. Substance use disorders can either directly or 
indirectly cause behaviors associated with conduct disorder.  This may be due to the cyclical 
relationship between substance use and conduct problems—aggressive behaviors increase use of 
substances, which in turn lead to more aggressive behaviors (White, Loeber, Stouthamer-Loeber, 
& Farrington, 1999). Therefore, it is not always easy to separate out conduct disorder in the 
presence of substance abuse, particularly within a substance use disorders treatment setting. One 
study showed that on initial screening, 95% of the adolescents being treated for substance abuse 
displayed a history of conduct disorder type behavior, but after more stringent assessment was 
conducted (e.g., exclusion of behaviors directly or indirectly related to alcohol or drug 
involvement) only 47% met criteria for conduct disorder (Brown, Gleghorn, Schuckit, Myers, & 
Mott, 1996). This suggests that approximately half of those who initially meet criteria for 
conduct disorder may display these behaviors as a result of their alcohol and other drug 
involvement, rather than having an independent conduct disorder (Brown et al., 1996). The 
difficulty of teasing out the effects of substance use disorders and conduct disorder, and its 
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association with attention difficulties makes the need to assess for childhood conduct problems 
particularly important when examining ADHD in a substance use disorders population.  
Comorbidities 
Although high comorbidity of substance abuse and mental health disorders reflects a 
small portion of the general population, these individuals account for a majority of individuals 
with severe impairment (Chan, Dennis, & Funk, 2008; Kessler et al., 2006). These compounding 
disorders can have significant negative implications in terms of the onset, course, severity, and 
treatment of substance use disorders (Arias et al., 2008). Both internalizing disorders (such as 
depression and anxiety) and externalizing disorders (such as CD and ADHD) are frequently 
comorbid with substance use disorders in adolescents, and may represent different pathways to 
the development of substance use disorders (Arias et al., 2008; Chan et al., 2008). The most 
common co-occurring problems include CD (74.2%), ADHD (63.6%), depression (54.7%), and 
traumatic stress (50.6%) (Chan et al., 2008). 
When looking at a large sample of adolescents and adults seeking treatment for substance 
abuse, two thirds of all patients had a co-occurring disorder in the year prior to treatment, and in 
particular, young adults were found to be most vulnerable to these co-occurring disorders (Chan 
et al., 2008). Thus, it is clear that in addition to addressing substance use disorders in treatment, 
particular attention to specific co-occuring problems that may influence treatment outcome also 
needs to be considered.  
Comorbid ADHD and Substance Use Disorders 
One of the most common comorbidities associated with the development of substance use 
disorders is ADHD although research to date has not pinpointed why this increased risk for those 
with ADHD to develop substance use disorders occurs (Charach, Yeung, Climans, & Erin, 2011; 
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Molina & Pelham, 2003; Wilens, 2004b; Wilens et al., 2011).  Based on the literature from both 
longitudinal prospective studies following children with ADHD into adulthood, and retrospective 
studies of those in treatment for substance use disorders, it is clear that the presence of comorbid 
substance use disorders and ADHD is not only higher than expected, but may have long term 
implications in terms of the development, course, and treatment of substance use disorders (Arias 
et al., 2008; Faraone, Wilens, Petty, Antshel, Spencer, & Biederman, 2007; Wilens, 2004b). 
Based on his review of the literature, Wilens concluded that “ADHD is associated with different 
characteristics of substance abuse: substance abuse transitions more rapidly to dependence, and 
lasts longer in adults with ADHD than those without ADHD” (Wilens, 2004a, p. 38). Studies 
looking at ADHD and substance use variables will be reviewed further below.  
Prospective longitudinal studies. Longitudinal studies have demonstrated that children 
with ADHD are at higher risk for developing substance abuse, particularly alcohol and nicotine 
use disorders (Charach et al., 2011; Mirza & Bukstein, 2011). A meta-analysis of 27 such 
longitudinal studies that followed children prospectively into adolescence and adulthood found 
that children diagnosed with ADHD are more likely to have ever used nicotine or other 
substances than their non-ADHD counterparts, and were more likely to develop substance use 
disorder for nicotine, alcohol, marijuana, cocaine or other drugs (Lee, Humphreys, Flory, Liu, & 
Glass, 2011). Across reviewed studies, these authors argued that early ADHD strongly predicts 
substance use disorders in adolescence and adulthood, regardless of the specific demographic 
and methodological factors across studies. They found that children with ADHD were 1.5 times 
more likely to develop substance use disorders across a range of substances (Lee et al., 2011).   
One of these studies examined the impact of specific ADHD symptoms and severity on 
use of drugs in 143 treatment-seeking adolescents diagnosed with ADHD, compared with 100 
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demographically similar adolescents (Molina & Pelham, 2003). Results showed that subjects 
with ADHD were not more likely than controls to have tried alcohol, cigarettes, or marijuana, 
but they were three times more likely to have used other illicit drugs including inhalants, 
hallucinogens, cocaine, and/or non-prescribed stimulants (Molina & Pelham, 2003). Although no 
differences in use were observed for alcohol, those with ADHD reported significantly more 
alcohol-related problems, indicating that childhood ADHD may be associated with greater 
impairment from drinking (Molina & Pelham, 2003). They also found that type of ADHD 
symptoms was important when predicting future behaviors. For instance, childhood symptoms of 
hyperactivity/impulsivity was associated with earlier initiation of cigarettes and illicit drug use, 
while the severity of childhood inattention symptoms predicted earlier first use of illicit drugs 
and prospectively predicted substance use outcomes, even after statistically controlling for 
ODD/CD symptoms (Molina & Pelham, 2003).  
Treatment status of adolescents with ADHD may also influence the likelihood of 
developing future substance use disorders (Biederman, Wilens, Mick, Spencer, & Faraone, 
1999). Biederman and his colleagues evaluated adolescent males diagnosed with ADHD over a 
4-year period (1999). They found that the participants who did not receive treatment (in this case 
ADHD medication) had a significantly higher risk of developing a substance use disorder 
compared to a either a control group without ADHD, or those diagnosed with ADHD who had 
received pharmacotherapy treatment (Biederman et al., 1999). 
Retrospective studies. In addition, retrospective studies of adults in substance abuse 
treatment for alcohol abuse also show a much higher prevalence of childhood onset and 
persistent ADHD (between 35% to 71%) than one would expect based on a prevalence rate of 3-
5% within the general population (Wilens, 2004b).  A recent meta-analysis reviewed prevalence 
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studies of ADHD within substance abuse populations, and found that of the 29 studies included, 
the pooled prevalence of ADHD was 23.1% in adults and adolescents irrespective of other 
variables such as age, gender, ethnicity, or setting (van Emmerik-van Oortmerssen et al., 2012). 
They also performed analysis on adults and adolescents separately, and found that the overall 
prevalence of ADHD in adult substance use disorder populations was 21.0% compared to 25.3% 
of adolescents (van Emmerik-van Oortmerssen et al., 2012), which is consistent with the 
research that symptoms of ADHD may be less severe in some adults (Barkley et al., 2006).     
For example, McAweeney, Rogers, Huddleston, Moore and Gentile (2010) 
systematically examined the prevalence of ADHD in 87 adult patients in treatment for substance 
use disorders, examining both prior diagnoses and conducting current evaluations. They sought 
to determine if the rate of ADHD was significantly higher when assessed by a psychologist 
compared to the rate ascertained from just previous diagnosis. Based on a review of client 
records, they determined that of 97 participants, only one had a previous clinical diagnosis of 
ADHD. However, these investigators found an additional 35 participants who met the full 
diagnostic criteria for ADHD after a thorough psychological assessment, including having 
symptoms since childhood (McAweeney et al., 2010).  
Conduct Disorder and ADHD 
While it is clear that there is an increased incidence of ADHD among both adolescent and 
adult populations with substance use disorders, the specific role that ADHD plays in the 
development of substance use disorders is less clear—particularly when considering the frequent 
comorbidity of conduct disorder with ADHD. The literature is mixed regarding the specific 
independent contributions of ADHD and CD to substance use disorders—some report that the 
effects of ADHD are not as significant when controlling for CD, others suggest that CD might be 
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a mediating factor between ADHD and SUD, while others propose that ADHD is an independent 
predictor of substance use disorders. 
Some researchers suggest that the link between substance use disorders and ADHD is 
overstated, and that this relationship is due to other factors, including the presence of CD 
(Lynskey & Hall, 2001). Unfortunately, these authors conducted a global substance abuse 
assessment, and did not differentiate the potential effects of ADHD by substance (Lynskey & 
Hall, 2001), while recent research has demonstrated that specific type of substance used may be 
influenced by ADHD symptoms (Molina & Pelham, 2003). Some studies suggest that the effects 
of ADHD are not significant or as large when controlling for comorbid CD (Flory & Lynam, 
2003; Torok, Darke, & Kaye, 2012), suggesting that CD, rather than ADHD symptoms, 
contributes to the development of substance use disorders. The Torok et al. study examined 
individuals who abused psychostimulants on at least a weekly basis for the past six months 
(2012). Their 269 participants were screened for ADHD using the Adult Self Report Inventory. 
Although they found that CD was a significant independent predictor of drug use behavior and 
strongly associated with risky substance use behaviors, self-reported ADHD symptoms were also 
found to independently predict substance use behaviors, although more weakly than CD (Torok 
et al., 2012). The Flory and Lynam study indicated that participants with both ADHD and CD 
had greater risks for substance abuse than those with either disorder alone, which suggests that 
there is an additive relationship between CD and ADHD, and that the effects of both disorders on 
substance abuse are greater than either one alone (2003).  
Others researchers have suggested that the relationship between substance use disorders 
and ADHD is mediated by CD, and factors such as a deviant peer group, rather than ADHD 
symptoms, influence the development of substance use disorders (Looby, 2008). This may be 
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possible, as conduct disorders have been shown to have a reciprocal relationship with substance 
use disorders, each exacerbating the expression of the other (Mirza & Bukstein, 2011). Conduct 
disorders may therefore be a mediating variable between ADHD and substance use disorders, 
and when the two are comorbid, they create a combined risk for developing substance use 
disorders that is greater than either disorder alone (Mirza & Bukstein, 2011).  
However, others investigators suggest that even when CD is statistically controlled for, 
there is a unique contribution of ADHD that predicts the onset of substance use problems 
(Elkins, McGue, & Iacono, 2007; Wilens et al., 2011).  Among adolescents, the degree of risk 
for developing substance use disorders appears to be related to specific drugs of abuse and 
particular ADHD symptoms (Looby, 2008). Moreover, factors often associated with ADHD, and 
not conduct disorder, have been linked to the increased risk for substance use disorders in youth 
diagnosed with ADHD including: academic dysfunction, cognitive deficits, and neurobehavioral 
disinhibition (Wilens, 2004b).  
Clearly, these various perspectives highlight the difficulties associated with disentangling 
the complex comorbid diagnoses associated with the development of substance use disorders, 
and demonstrates the need to control for conduct problems to determine the unique contribution 
of ADHD on substance use disorders. Regardless of our understanding their unique 
contributions, it is clear that the combined effect of both ADHD and CD can be detrimental. 
Patients with the additional co-occurring diagnosis of conduct disorder along with ADHD have 
been found to have the poorest outcomes in terms of their long-term course of substance abuse 
(Wilens et al., 2011).  The development of more efficacious treatments for those with both 
substance abuse and these co-occuring disorders may depend on better understanding how each 
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contributes to substance abuse pattern and motives along with their impact on recovery.  
Determining associated differences will allow the development of targeted treatment plans.  
What Distinguishes Substance Abuse Patients with ADHD 
Although the specific pathways between the development of ADHD and substance use 
disorders are unclear, it appears that ADHD is significantly associated with substance use 
disorders and often goes unrecognized.  This increased risk for children and adolescents with 
ADHD to develop substance abuse is significant for both research and clinical practice due to the 
implications it has for earlier identification, treatment, and recovery of individuals with both 
disorders. The opportunity for more targeted treatment approaches at earlier stages in their 
expression of symptoms could lead to better long-term outcomes for co-occurring mental health 
and substance abuse disorders (Wilens, 2004a). The identification and treatment of unrecognized 
ADHD within a substance use disorder population could greatly impact the course and success of 
treatment.  
Prior research has focused on the prevalence of co-occurring ADHD and substance abuse 
and suggested a negative impact on treatment but has not examined how such individuals differ 
from other young adults with substance abuse. Research is needed to determine the effects of 
ADHD with and without conduct problems, and to determine how young adults with substance 
abuse problems and ADHD differ in terms of factors that could influence substance abuse 
treatment. Possible factors that may help clinicians understand the impact of co-occurring 
ADHD and substance use are substance abuse patterns, motives for use, as well as executive 
functioning.   
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Substance Abuse Patterns 
 
In terms of substance abuse, the literature has not systematically examined the 
differences between those with substance use disorders and those with co-occurring ADHD. 
However a number of studies primarily examining prevalence of ADHD have reported such 
differences.  For example, Ohlemeier and his colleagues (2008) looked at ADHD retrospectively 
in adult patients in inpatient substance abuse treatment (N=152) with either alcohol dependence 
(n=91) or multiple substance addiction (n=61). In the alcohol dependent patients, both the age 
when first commencing alcohol use and the age at which they exceeded a critical level of alcohol 
use were significantly younger in the group with ADHD than those without (Ohlemeier et al.). 
This was also true for the patients addicted to multiple substances—a significantly lower age of 
first consumption was found for each of the drugs assessed in those with ADHD compared to 
those without ADHD including: marijuana, amphetamines, cocaine, and heroin (Ohlemeier et 
al.).  This suggests that childhood ADHD predisposes some adolescents to develop substance 
abuse problems earlier, and given that earlier age of onset is a predictor of long term severity of 
substance use, ADHD’s effect on age of onset may negatively impact both the progression and 
course of substance use disorders (Arias et al, 2008; Ohlemeier et al., 2008).  In addition, ADHD 
has been associated with higher relapse rates after successful substance abuse treatment, which 
suggests that the necessity of managing both ADHD in addition to their substance use has a 
negative impact on the treatment and possibly the recovery process of those with comorbid 
substance use disorders and ADHD (Carroll & Rounsaville, 1993). 
It is hard to interpret this literature because different investigators have examined 
different substance abuse populations (i.e., drug of choice such as alcohol, stimulants, opiates, 
etc.), settings (e.g., inpatient vs. outpatient), and different substance use variables. Potential 
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variables of interest are: age of onset of alcohol use, age of onset of alcohol problems, duration 
of alcohol problems, lifetime number/types of other illicit drugs used (particularly abuse of 
stimulants), smoker status and years smoked, number of unsuccessful attempts to quit drinking, 
age of first treatment for substance use disorders, number of past substance abuse treatments 
excluding detox, longest period of active treatment, and longest period of abstinence. There 
certainly could be pre-existing difference between the groups or third variables such as age or 
presence of conduct problems that account for some of these differences. Moreover, some results 
or findings related to how the substance use patterns or those with ADHD differ have been 
inconsistent. Nevertheless, an attempt was made to review the major studies found examining 
substance abuse differences which are listed in Table 1. The substance abuse patterns examined 
can be broadly broken into several categories: course of use and development of problems, as 
well as age at treatment and treatment attempts.      
The literature appears to suggests that those with ADHD have an earlier age of first 
substance use (Arias et al., 2008), and studies looking at participants’ initial use of alcohol 
(Schubiner et al., 2000) and cocaine use (Carroll & Roundsaville, 1993), indicated that 
participants with comorbid ADHD tended to start using substances at an earlier age than those 
without comorbid ADHD. As discussed previously, this is important, because those who start use 
of and experimentation with substances earlier tend to also develop problematic use earlier than 
their peers (Hingson et al., 2006; Rohde et al., 2001). The literature was generally consistent, 
although the results were not always statistically significant. For example, in Levin and 
colleagues study of cocaine abusers with ADHD they tended to have earlier onset of initial and 
regular cocaine use but this trend was not statistically significant (Levin, Evans, & Kleber, 
1998).  Other studies found significant results in terms of age of development of substance use 
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disorders including: multiple substance dependence diagnosis (Arias et al., 2008), more severe 
and earlier cocaine abuse (Carroll & Roundsaville, 1993) alcohol tolerance/loss of control of 
drinking (Johann, Bobbe, Putzhammer, & Wodarz, 2003) or alcohol dependence (Schubiner et 
al., 2000). Again, even within studies, results were not necessarily significant for other drugs 
(Schubiner et al., 2000), and it is difficult to draw firm conclusions about the earlier age of onset 
of use or problematic use, although it appears that those with comorbid ADHD tend to use and 
develop problems with substances earlier than their peers without ADHD.  
Related to the severity of problems and treatment, the literature suggests that those with 
ADHD are more likely to seek treatment earlier for substance use disorders, which may indicate 
more severe problems at an earlier age. For instance, in a study of cocaine abusers in treatment, 
those with childhood ADHD were younger at presentation for treatment and reported more 
severe substance use, as well as more previous treatment/higher rates of relapse after successful 
treatment (Carroll & Roundsaville, 1993). Other studies of people with alcohol problems who 
were in treatment, found similar results—those with comorbid ADHD were younger at age of 
first treatment for alcohol dependence, and had both a significantly higher daily alcohol intake, 
and intake per month (Johann et al., 2003), and women with ADHD had a higher number of 
treatments for alcohol abuse (Schubiner et al., 2000). In a study that examined the length of stay 
in a residential treatment center, the mean number of days in treatment was lower in ADHD 
group, but this result was not statistically significant (McAweeney et al., 2010). In a study 
examining those in treatment for methadone, researchers for that those who self-reported 
attentional difficulties were less likely to be successful in treatment, defined as abstinence nine 
months after admission to treatment, than their peers that did not report difficulties with attention 
(Kolpe & Carlson, 2007).  Based on the literature, it is not clear if those with comorbid ADHD 
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have more treatment attempts and are less successful than their peers in treatment, but it is clear 
that there is need for further examination of these variables, particularly as they may be related to 
factors that could influence treatment. It is important to explore the specific factors that make 
those with ADHD in substance abuse treatment different than those with substance use disorders 
alone, in order to improve their long-term outcomes for both treatment and recovery. 
Table 1. Substance Abuse Patterns in ADHD Comorbid Substance Abuse Patients 
Reference 
Source  
Study Population, Design, 
and measures used  
Substance Abuse 
variables examined  
Findings  Comments  
Arias et al., 
2008 
N= 1,761 adults (not in 
treatment) with lifetime 
diagnosis of cocaine and/or 
opioid dependence. 
Retrospectively compared 92 
participant with LIFETIME 
ADHD (5.22%) with rest of 
the sample. Semi-structured 
assessment for drug 
dependence and alcoholism 
(SSADDA)  
1. Prevalence of 
dependence 
diagnosis, 2. Age of 
first use,  3. Age at 
first dependence                  
4. Hospitalization for 
substance use and 
psychiatric disorders  
ADHD group had 
earlier age of first 
substance use, more 
substance dependent 
diagnosis, even when 
controlled for CD and 
BPD.  
Only looked at when 
dependent on a 
drug, not abused  
Carroll & 
Roundsaville, 
1993 
N= 298 cocaine abusers, half 
from inpatient and half 
outpatient treatment settings. 
Retrospectively compared 
35% of sample that met 
DSM-III criteria for 
childhood ADHD with rest of 
the sample.  
 
Addiction Severity Index, 
ADHD= DSM-III criteria 
SUD= CIDI substance 
module, ADHD= Wender 
and by DSM-IV criteria 
1. Substance use 
severity and patterns, 
2. level of 
functioning, and 3. 
SUD related 
problems  
Cocaine abusers with 
childhood ADHD were 
younger at presentation 
for treatment and 
reported more severe 
substance use, earlier 
onset of cocaine abuse, 
more frequent and 
intense cocaine use, 
intranasal rather than 
freebase or intravenous 
use of cocaine, higher 
rates of alcoholism, and 
more previous 
treatment/higher rates 
of relapse after 
successful treatment.  
Not current ADHD 
symptoms, only 
lifetime or 
childhood  
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Johann et al., 
2003 
N= 314 Alcoholics in 
inpatient treatment. 21.3% 
had lifetime ADHD with 
ongoing symptoms into 
adulthood. Compared 314 
alcoholic to 222 unrelated 
healthy subjects 
Differences in use 
and severity of SUD 
Alcoholics with ADHD 
had a younger age at 
onset of tolerance/ loss 
of control of drinking, 
compared to those 
without ADHD. They 
were also younger at 
age of first treatment 
for alcohol dependence. 
They had a significantly 
higher daily alcohol 
intake, intake per 
month. Alcoholics with 
ADHD had more 
lifetime court 
proceedings against 
them. There was no 
significant differences 
in social complications 
such as unemployment 
or divorce.  
They did not find 
any differences in 
terms of 5-HTT 
genotype or 5-HT2c 
allele between those 
with comorbid 
ADHD and those 
without, which 
suggested to these 
investigators that the 
comorbidity forms a 
unique phenotype, 
based on 
interactions with the 
environment, which 
leads to more severe 
substance use 
disorders.  
Kolpe & 
Carlson, 2007 
N=687 patients in a 
methadone maintenance 
program, 19% of the sample 
reported attention symptoms 
that interfere with 
functioning. Retrospectively 
compared those with 
symptoms of ADHD to those 
without. ADHD= Attention 
Deficit Disorder Screen  
Success of treatment  
9 months after 
admission 
Those who reported 
ADHD were less likely 
to be highly successful 
in treatment, defined as 
abstinence, than those 
who did not report 
ADHD symptoms  
 
Levin et al., 
1998 
N= 281 cocaine abusers 
seeking outpatient treatment, 
12% of the sample met 
criteria for childhood ADHD 
79% of those had current 
symptoms; required "current" 
cocaine use as defined within 
the past 3 weeks but not the 
past 4 days. Compared those 
with CURRENT ADHD to 
those without ADHD. SCID 
for DSM-IV, SCID-like 
module (KID-
SCID)=ADHD; Pattern of 
Drug Use Questionnaire 
Age of first use, age 
of regular use, 
amount spent prior to 
treatment ($), # of 
days used prior to 
treatment, period of 
longest abstinence, 
prevalence of other 
psychiatric disorders, 
current 
abuse/dependence on 
alcohol, marijuana, or 
nicotine  
Those with ADHD had 
more substance use 
disorders, including 
marijuana dependence. 
Non- significant trend 
for those with ADHD 
or subthreshold ADHD 
symptoms to have 
earlier onset of initial 
and regular cocaine use, 
to spend more money 
on cocaine in the month 
prior to treatment 
They also asked the 
patients if they felt 
that drug use 
improved, 
worsened, or had no 
impact on their 
ADHD symptoms 
They found that 
11% of the sample 
reported symptoms 
of ADHD developed 
after regular drug 
use, potentially 
suggesting another 
diagnostic category 
of those with 
secondary ADHD 
symptoms  
Ohlemeier et 
al., 2008 
N= 91 patients within alcohol 
dependence inpatient 
treatment. Retrospectively 
compared those with ADHD 
to those without ADHD. 
ADHD= Wender, DSM-IV 
checklist, CAARS 
Use of alcohol and 
use of nicotine, age 
of first use of alcohol, 
age when alcohol 
exceeded critical 
level  
Patients with ADHD 
showed "average to 
high" nicotine 
dependence, Alcohol 
addiction started at an 
earlier age in the 
ADHD patients, but 
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this result was not 
statistically significant 
Schubiner, et 
al., 2000 
N=201 patients in treatment.  
Retrospectively compared 
those with ADHD + CD, 
ADHD only, and CD only to 
a group without ADHD or 
CD. SCID for DSM-IV, 
DSM-IV criteria for ADHD; 
ASI 
Age of onset of abuse 
or dependence for 
specific drugs, 
number of treatments 
for alcohol 
abuse/dependence, 
number of treatments 
for drug 
abuse/dependence,  
Those with ADHD 
were more likely to 
have motor vehicle 
accidents, and women 
with ADHD had a 
higher number of 
treatments for alcohol 
abuse. No statistical 
significance in 
psychiatric 
comorbidities. Those 
with ADHD tended 
towards earlier age of 
alcohol dependence, but 
age of onset of all other 
drugs was not 
significant.  
 
McAweeney, 
et al., 2010 
N= 87 patients in residential 
treatment. Retrospectively 
compared those with ADHD 
to those without. Stage 1: 
Reviewed records for 
previous ADHD diagnosis, 
Stage 2: ADHD=ASRS and 
DSM-IV criteria follow up  
Length of stay in a 
residential treatment 
center  
The mean number of 
days in treatment was 
lower in ADHD group, 
but this was not 
statistically significant  
 
 
Motives for Use 
It is important to understand patients’ motivations to use alcohol and other drugs in order 
to best tailor intervention and treatment approaches to most efficiently address their difficulties. 
Research suggests that cognitive processes such as expectancies and motives are central to 
alcohol and other drug use (Cooper, 1994; Cox & Klinger, 1988; Doyle, Donovan & Simpson, 
2011; Kuntsche, Knibbe, Gmel, & Engels, 2005), and understanding and taking into account 
specific motivations for use of substance could beneficially influence treatment (Doyle et al., 
2011).   
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General population studies of motives reveal that there are generally four types of 
motives for substance use including coping, enhancement, social, and conformity motives. These 
four motives reflect an underlying two dimensional model originally used in the drinking 
motives literature including valence (positive or negative reinforcement) and the source of 
outcomes expected (internal or external) (Cooper, 1994; Cox & Klinger, 1988). Coping refers to 
using substances to regulate or reduce negative internal emotions while conformity refers to 
avoiding negative social consequences. Enhancement and social motives reflect positive 
reinforcement, and refer to wanting to increase positive mood or well-being or obtain positive 
rewards respectively.  
It is also argued by some authors that different motives for using substances are 
motivated by different needs and therefore associated with specific consequences (Kuntsche et 
al., 2005). For instance, it is clear from the literature that those who have more problematic 
drinking are those who are more likely to drink for individual reasons, including changing their 
mood state (coping and personal enhancement motives), rather than drinking for primarily social 
(including conformity) reasons (Doyle et al., 2011). While social reasons for drinking are still 
relevant for those seeking treatment for substance use disorders, using substances to avoid 
negative social consequences, such as in conformity have been studied less in adult populations.       
An article reviewing drinking motives within young people indicate that, at least initially, 
most youth drink primarily for social reasons, others indicated drinking for enhancement reasons 
and even less reported drinking for coping reasons (Kuntsche et al., 2005). While personal 
enhancement motives predicted difficulties, drinking for coping reasons, particularly drinking to 
cope with negative emotional states was found to be associated with the most alcohol-related 
problems.   Another study specifically aimed at exploring substance use motives among young 
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people seeking mental health treatment reported that positive and negative drug effects, social 
reasons, and coping to be the most common reasons for use for both those with and without 
substance use disorders (Hides, Lubman, Cosgrave, Buckby, Killackey, & Young, 2008). The 
investigators reported that the participants with current substance use disorders scored higher on 
all the scales, with using substances for coping and drug effects being related to more severe 
symptoms and lower levels of functioning (Hides et al., 2008). 
 In the area of substance abuse and various co-morbidities, authors often discuss the 
possibility of self-medication as a type of coping motive, using substances in order to reduce 
psychiatric symptoms, including  ADHD (Blume, Marlatt, & Schmaling, 2000; Rosenthal & 
Westreich, 1999; Wilens; 2004) The concept of self-medication was originally based on the work 
of Khantzian and has been termed the “self-medication hypothesis”; he suggested that those with 
psychiatric disorders often report choosing specific substances with compensatory stimulating or 
sedating action, such as those with ADHD choosing to use amphetamines rather than alcohol, 
due to its stimulating properties (1997). Further, the self-medication hypothesis suggests that this 
pattern of use predisposes them to addiction, as use of substances functions as a compensatory 
behavior in order to regulate affect and self-sooth for the purposes of coping, and achieving 
emotional stability (Khantizian, 1997; Suh, Ruffins, Robins, Albanese, & Khantzian, 2008). 
The general substance use disorders literature is conflicted regarding this self-medication 
hypothesis, as certain substances may actually worsen psychiatric symptoms rather than relieve 
them. While the “dysphoria relief” has been found to be the most frequently endorsed reason for 
substance use among those with psychiatric problems  (Gregg, Barrowclough, & Haddock, 
2007), reducing negative emotional and cognitive states and augmenting positive states are also 
commonly cited reasons for using alcohol and other drugs (Carey et al., 1999). Self-medication 
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of psychiatric symptoms has been one of the least commonly endorsed reasons for use of 
substances within the literature, particularly in terms of alcohol or marijuana (Carey et al., 1999; 
Thornton, Baker, Johnson, Kay-Lambkin, Lewin, 2012). This is possibly because substances 
may actually exacerbate underlying psychiatric symptoms. One notable exception to this has 
been tobacco, which several studies suggest may be frequently used in a psychiatric population 
to medicate such symptoms (Carey et al., 1999; Thornton et al., 2012). Some point to the fact 
that some substances may in fact cause, as well as exacerbate current psychiatric disorders, and 
suggest a bio-behavioral rebound model to explain how substances can initially reduce and then 
later exacerbate symptoms (Blume et al., 2000). In any event, in its broader form self-medication 
refers to the motive to use alcohol or other drugs so as to change dysphoric affect that may be 
associated with comorbid problems.   
In an Australian study of patients with serious mental illness in addition to substance use 
disorders, they examined the motives for use for alcohol, nicotine, and marijuana (Thornton et 
al., 2012) They found that in 64 participants, tobacco was used most frequently for coping 
motives, alcohol was associated most frequently with social motives, and marijuana was 
frequently used for pleasure enhancement motives (Thornton et al., 2012). In addition, they 
asked qualitative questions about motives for use, and found that substance use to cope was 
associated with using to cope with stress, escape reality, and self-medicate. Tobacco was most 
commonly associated with self-medication, but some participants also described using alcohol 
and marijuana to cope with mental illness symptoms (Thornton et al., 2012), which suggests that 
perhaps the patient believes that substances are, at least intermittently, reducing or alleviating 
their psychiatric symptoms (Blume et al., 2000). When they asked specifically about the impact 
of substance use on mental health, they found that tobacco was associated with positive mental 
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health effects, while alcohol and marijuana were associated with negative impacts on mental 
health (Thornton et al., 2012).  
Notably, much of the motives literature in patients with comorbid substance use disorders 
has been conducted on patients with trauma and severe mental illness. One study mentioned 
earlier, examined the motives for use within non-psychotic youth (15-24) seeking treatment for 
mental health concerns, such as depression and anxiety, who had used alcohol or other drugs 
within the past year (Hides et al., 2008). They found that 27.5% of that population had comorbid 
substance use disorders, with alcohol and marijuana use disorders being most common. Those 
with comorbid substance use disorders were more likely to score higher on the motives for use 
scales, and those who endorsed motives for coping and drug effects (including positive drug 
effects such as helping them think/concentrate) were more likely to have higher levels of anxiety 
and depression, and lower levels of functioning (Hides et al., 2008). 
The most recently developed measure for examining drinking motives is the Desired 
Effects of Drinking (DEOD) Scale developed as part of the national COMBINE study which 
examined combining cognitive behavior therapy (CBT) with medications (Doyle et al., 2011). 
The DEOD was used in the CBT conditions to assess and provide feedback to 572 adult patients 
seeking alcohol treatment regarding their motives for alcohol use and was used in their personal 
treatment plan. Analysis of the findings within this treatment seeking sample found that three 
general motives or factors (i.e., to reduce or control negative affect (coping), to increase positive 
affect (enhancement), and to socialize with others (social)) best described the motives for use 
(Doyle et al., 2011). In addition, these three general factors were further broken down into nine 
subscales tapping into various motivations to drink which could be used to provide the 
participants with specific feedback and in treatment planning. The subscales of the DEOD  
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include the following: to feel more powerful and courageous (Assertion); to get drunk, recover 
from a hangover, or sleep (Drug Effects); to feel more alert or increase concentration (Mental); 
to reduce negative affect (Negative Feelings); to relax or increase positive affect (Positive 
Feelings); to feel more satisfied and less disappointed with oneself (Self-Esteem); to find relief 
against problems and tension (Relief); to feel more romantic and sexually excited (Sexual 
Enhancement); and to be sociable and comfortable in social settings (Social Facilitation). Within 
this treatment-seeking population, coping motives were found to be most strongly associated 
with drinking problems and drinking-related consequences (Doyle et al., 2011). 
 As much of the motive literature to date has been done on the general population, 
including adolescents and young adults, who endorse different motives for use than those with 
more severe problems with substance use, this study is important because it identifies motives 
associated with more problematic and severe use within a treatment seeking population. 
Unfortunately, although this study included those with comorbid mental health disorders, they 
did not analyze if those with different co-occuring disorders might have different profiles in 
terms of motivation for use.  
Aside from the discussion of self-medication in the comorbid ADHD and substance 
abuse literature, the author could not find any studies empirically examining motives for drinking 
or substance use within an ADHD population. It might be predicted that coping motives 
generally, and more specifically mental effects related to improving concentration and focus, 
might be more implicated in those with ADHD given their difficulties with concentration and 
attention, and the impact on everyday adjustment. 
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Executive Functioning 
It is difficult to define executive functioning due to the diversity of opinions regarding the 
exact nature and functions of executive functioning.  However, the prominent symptoms 
involved in ADHD (including impulsivity and difficulties staying on task and being organized) 
clearly overlap with executive functioning. One definition of executive functioning within the 
field of substance abuse includes the ability to engage in goal driven activities which consist of 
the following components: planning, organizing, problem solving, decision-making, initiating 
and self-regulating behavior, working memory and motivation (Blume & Marlatt, 2009). 
Another definition that captures possible deficits in problem solving states:  
“The executive functions are a collection of processes that are responsible for guiding, 
directing, and managing cognitive, emotional, and behavioral functions, particularly 
during active, novel problem solving. The term executive function represents an umbrella 
construct that includes a collection of inter-related functions that are responsible for 
purposeful, goal-directed, problem solving behavior” (Gioia, Isquith, Guy, & Kenworthy, 
2000, p. 1).  
Deficits in executive functioning can impair an individual’s ability to plan, and follow through 
on tasks. It can influence his/her ability to delay gratification in exchange for future oriented 
benefits, and can impair his/her ability to reach broader goals—such as successfully entering and 
completing substance abuse treatment.    
Executive Functioning in ADHD  
Adult ADHD appears to involve significant deficits in executive functioning in daily life 
(Barkely & Murphy, 2011). In fact, deficits in executive functioning are discussed as an 
underlying neuropsychological disorder, and current theories of ADHD place emphasis on the 
central role of attentional and executive dysfunctions.  Barkley’s model of ADHD proposes that 
ADHD is linked to behavioral inhibition and four other executive functions including:  (1) 
working memory, (2) self-regulation of affect-motivation-arousal, (3) internalization of speech, 
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and (4) reconstitution (behavioral analysis and synthesis) (Barkley, 1997). The interaction of 
these elements inhibits individuals with ADHD to effectively self-regulate, and successfully 
engage in goal-directed behavior.  
Although these deficits are widely accepted as integral to ADHD symptoms, their 
specific cause is still contested due to the difficulty of teasing out these specific deficits from 
other neurological processes. For instance, Halperin and Schulz (2006) proposed a 
neurodevelopment model of ADHD that suggests that that prefrontal cortex is not the only, or 
even primary, brain structure affected by ADHD. Rather, they suggest that the prefrontal cortex 
serves as a “top-down” regulatory or executive control for coordinating multiple systems within 
the brain (Halperin & Schulz). Their model is based on a review of the literature that points to 
the inconsistency regarding the specific deficits involved in ADHD, and the tendency of 
symptomatology of ADHD to remit somewhat over time, suggesting a neurodevelopmental 
course of ADHD (Halperin & Schulz). Although multiple studies with both children and adults 
with ADHD using neuropsychological testing have demonstrated measurable deficits in 
executive functioning, including: inhibitory control, regulation of attention, planning, working 
memory, and shifting sets, these results are not consistent (Halperin & Schulz), and ADHD 
symptoms may be only weakly correlated with neuropsychological tests of executive functioning 
(Barkley et al., 2008; Jonsdottir, Bouma, Sergeant, & Scherder, 2006).  This has led some to 
suggest that ADHD is not a disorder of executive functioning, or only a subset has deficits in this 
area (Jonsdittir et al., 2006).  
Barkley suggests that perhaps this conclusion is based on the erroneous assumption that 
executive functioning tests are the gold standard for the presence of deficits in executive 
functioning (Barkley & Murphy, 2011).  He suggests that neuropsychological tests of executive 
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functioning may have low ecological validity. These tests tap into multiple cognitive processes 
besides just those of executive functioning, and sample such a small period of time, in which it is 
difficult to measure the full implication of difficulty with executive functioning specifically, and 
goal-directed behaviors in general (Barkley & Murphy, 2011), which the work of Halperin and 
Schulz seems to support. Rather, Barkley suggests that ratings of executive functioning in daily 
life may better measure the full range of difficulties across time, and created a scale to assess for 
deficits of executive functioning in daily life based —the Barkley Deficits in Executive 
Functioning Scale (B-DEFS) (Barkley & Murphy, 2011).   
The B-DEFS was constructed based on current theories of executive functioning and 
represents five underlying dimensions of executive functioning: self-management to time, self-
organization/problem-solving, self-discipline or inhibition, self-motivation, and self- regulation 
of emotions. Three groups were compared on the B-DEFS and a standard battery of executive 
functioning tests including: adults diagnosed with ADHD (N=146), a clinical control group of 
individuals with subclinical ADHD symptoms (N=97), and a community sample without ADHD 
(N=109). They found that those with ADHD reported more severe symptoms on the B-DEFS 
compared to either the clinical or community sample, but was not significantly related to the tests 
of executive functioning. In addition, most of the ADHD sample fell into the “clinical 
impairment” range on the B-DEFS, but only a minority were found to have clinical impairment 
based on the tests of executive functioning (Barkley & Murphy, 2011). Only two tests of 
executive functioning were found to share small but significant variance with the B-DEFS scale, 
the Continuous Performance Test (used to assess inattention and inhibition) and the Five-Points 
Test (used to assess nonverbal working memory and fluency). They concluded that ADHD does 
involve substantial difficulties with executive functioning in daily life, and that these difficulties 
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were more likely to be associated with rating of executive functioning, rather than tests of 
executive functioning (Barkley & Murphy, 2011). In fact, deficits in such areas may have 
significant implications for substance abuse treatment outcomes that require long term goal-
directed behaviors, such as treatment retention and consistent focus on intermediate life goals.   
Executive Functioning in Substance Abuse 
 There is also literature that indicates deficits in executive functioning accompany 
substance abuse and may be linked to the abuse of a wide range of addictive substances (Blume 
& Marlatt, 2009; Vik, Cellucci, Jarchow, & Hedt, 2004).  In a review of different substances and 
their effect on neuropsychological functioning, there is consistent evidence across substances 
that they negatively impact  executive functioning, attention, learning, memory, and visual 
spatial abilities, and may be robustly associated with impulsivity, working memory, and 
decision-making (Yücel, Lubman, Solowij, & Brewer, 2007). However, most studies are cross-
sectional in nature, making it difficult to determine if the deficits are as a result of the substance 
abuse, related to pre-existing vulnerabilities, or some combination of both. There is likely an 
intricate relationship between pre-existing neuropsychological vulnerabilities, age of initiation of 
substance use, and patterns of substance use (Blume & Marlatt, 2009; Vik et al., 2004).  
The development of brain structures continues to mature into early adulthood, particularly 
the frontal lobe which has been linked to the regulation of executive functioning and memory. 
Preexisting deficits in executive functioning may predispose some individuals to substance use 
disorders, which in turn exacerbate their deficits in executive functioning (Giancola & Tarter, 
1999; Nigg et al., 2004). Long-term, heavy drug use or alcohol use also has been demonstrated to 
influence the neuroanatomy of the brain, as well as influence neuropsychological functioning. 
More robust, longitudinal research is needed in order to determine the degree to which such 
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executive functioning deficits are present prior to, or are more a result of substance use (Giancola 
& Tarter, 1999).  
In addition, similar to the literature of attention and executive functioning, it is difficult to 
tease out the effects of substance use disorders on executive functioning due to the conflicting 
literature with small sample sizes and heterogeneous samples, and different tests of executive 
functioning. For instance, when looking at heavy social drinkers within non-clinical participant 
samples, a meta-analysis concluded that the literature has not always produced consistent results 
in this area, and that this may be a function of not comparing heavy social drinkers to normal 
drinkers and the number and type of executive functioning tasks administered (Montgomery, 
Fisk, Murphy, Ryland & Hilton, 2012). In addition, different tasks were used in each of the 
studies they analyzed which they determined was problematic because these tests of executive 
functioning used may involve additional neural structures than the tests were designed to 
administer, possibly confounding results (Montgomery et al., 2012). They concluded that 
additional research was needed to determine if it was methodological limitations that produced 
inconsistent results. These authors conducted another study, which compared forty-one college 
student non-clinical participants on their level of alcohol use, and found that those who were 
heavier social drinkers exhibited deficits in executive functioning tests compared to their peers, 
particularly on tasks of switching, inhibition, and access to semantic memory (Montgomery et 
al., 2012).  
Several studies have examined self-report measures that tap into components of executive 
functioning (Heffernan, Moss, & Ling, 2002; Lyvers, Duff, & Hasking, 2011). Lyvers, et al 
found a significant relationship between risky drinking and self-reported deficits in executive 
functioning within their sample of 132 adults ages 16-68 years of age. Within a community 
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sample, they examined several variables related to risky alcohol use, including motives for use 
such as reward sensitivity and sensitivity to punishment, as well as a self-report frontal lobe 
measure that examined apathy, disinhibition, and executive dusfunction (Lyvers et al., 2011). 
They found that impulsivity, reward sensitivity, and family history of alcoholism were related to 
more risky drinking, which may influence the predisposition to heavier and riskier alcohol use.  
Specifically, they found that rash impulsiveness and sensitivity to reward, defined as the degree 
to which behavior tends to be motivated by positive reinforcement, or inhibition of behavior, 
partially mediated the relationship between disinhibition and drinking behavior which often leads 
to riskier and more problematic alcohol consumption.  
Another study using a self-report measure examined prospective memory, which refers to the 
memory for future events or remembering to do things at some future point in time (e.g. attend 
appointments) (Heffernan et al., 2002). Working memory and executive functioning processes 
are closely related, as the working memory capabilities may influence an individual’s ability to 
manipulate information needed for executive functioning (Piechatzek et al., 2009). Heffernan’s 
study examined heavy social drinking young adults from a community sample that had never 
been diagnosed as alcohol dependent. Thirty participants in the heavy, chronic group were 
compared to thirty participants in the low-dose/alcohol free group on a self-report measure of 
prospective memory including short-term habitual prospective memory (e.g. “I forgot to turn my 
alarm clock off when I got up this morning”), long-term episodic prospective memory (e.g. “I 
forgot to pass on a message to someone”), and internally cued prospective memory (e.g. “I forgot 
what I wanted to say in the middle of a sentence”). They found that the chronic heavy alcohol 
group reported significantly more deficits in all types of prospective memory, and the results 
remained significant even when controlling for the use of other drugs, as well as the number of 
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strategies that they used to help aid their memory (Heffernan et al., 2002). Taken together, these 
studies suggest that executive functioning deficits are able to be examined using self-report 
scales, and that there are significant differences in terms of memory and executive functioning 
deficits depending on amount of alcohol consumed.  
Combined Influences 
Deficits in executive functioning appear to be a construct that is very relevant to both 
ADHD and young adults with substance abuse problems. Pre-existing deficits in executive 
functioning among ADHD adolescent and young adults may put them at greater risk for 
problematic involvement with alcohol and other drugs. Early use would then be predicted to 
exacerbate problems in executive functioning.  Consequently, individuals with co-occurring 
ADHD and substance abuse might be expected to exhibit even greater difficulties in executive 
functioning possibly across more domains.  
Purpose of the Present Study and Research Questions 
There is considerable literature documenting that ADHD is a risk factor for the 
development of substance abuse problems and that, in fact, a significant portion of young adults 
in substance abuse treatment (as many as 20%) have unrecognized ADHD (van Emmerik-van 
Ootmerssen et al., 2012).
 
Although there have been many studies that have demonstrated an 
increased prevalence of ADHD within a substance abuse population, this study sought to extend 
the literature by researching possible differences characterizing substance abuse patients with 
ADHD, particularly differences that could have implications for better serving such patients in 
treatment. Based on the preliminary reported negative outcomes for patients with comorbid 
ADHD and substance use disorders, it is proposed that substance use patterns, motives for use, 
and executive functioning are potential key differences that could have implications for treatment 
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planning among this subgroup of substance abuse patients.  As this proposed project is the first 
attempt to characterize such differences, this study is exploratory in nature.  
We hypothesize that young adults with comorbid ADHD and substance use disorders will 
differ from those with substance use disorders alone in key ways: 1) Individuals with comorbid 
ADHD will initiate alcohol use earlier, have problems with alcohol earlier and for a longer 
period of time, report an earlier first age of treatment for substance use disorders with more 
unsuccessful attempts to quit drinking. In addition, they may also use more substances, both licit 
(including nicotine), and illicit (including stimulants).  2) Individuals with comorbid ADHD may 
have a different profile of motives for drinking or stimulant use with greater coping motives, and 
particularly report using alcohol or other drugs for “mental” effects, and 3) Individuals with 
comorbid ADHD would be expected to report more problems in the area of executive 
functioning overall, and specifically may report more problems with self-management to time 
and self-activation/concentration.
  
 
CHAPTER 2: METHODS 
Participants 
Participants were recruited from a local outpatient substance abuse treatment facility and 
included 23 young adults ages 18-35 who were enrolled in substance abuse treatment and gave 
consent. The rationale for the age restriction was to focus specifically on young adults who are 
most likely to have problematic substance use disorders and continuing ADHD; however in 
order to increase the sample it was extended to age 35. They filled out a demographic 
information form including age, sex, race/ethnicity, marital status, as well as history about 
education, employment, and any prior diagnosis of a mood or attention disorder.  
Participants fell into one of two groups based on a prescreening: those who have an 
alcohol and other drug use disorder diagnosis alone and those who have comorbid substance 
abuse and childhood and current symptoms of ADHD. Potential participants were excluded if 
they had cognitive confusion which would prohibit them from answering the self-report 
questionnaires or a history of brain injury, which could impair executive functioning independent 
of ADHD. One potential participant was excluded after completing a screening based on a 
history of traumatic brain injury. In addition, participants could not be acutely withdrawing from 
any substance (i.e., defined as no problematic use for the month prior to data collection), as 
active use or acute withdrawal would be expected to affect results.  
Procedures 
Participants were recruited in a variety of ways. First, researchers worked with the 
substance abuse agency and their counselors to get out word about the study. The primary 
investigator met with counselors and staff at the substance abuse agency and invited them to 
refer potential participants. In addition, 1-page recruitment flyers were posted about the study 
 37 
 
inviting participants to contact their counselor or the researcher for more information, and study 
researchers met with therapy groups and described the study and invited interested parties to 
complete a prescreen. All potential participants went through the informed consent process (see 
Appendix A) and completed the pre-screen to determine if they qualify for the study. If they 
qualified, they completed the rest of the measures and received a $10 Walmart gift card for 
participation.  
Potential participants were identified and classified into the study groups based on their 
scores on two pre-screening measures, the Wender Utah Rating Scale and the Adult ADHD Self 
Report Scale (ASRS), assessing childhood and adult symptoms of ADHD respectively. 
Participants needed to score above a 46 on the Wender, and endorse 4 of 6 current symptoms on 
the ASRS to be included in the comorbid ADHD group, or score less than 36 on the Wender and 
endorse no more than 2 of 6 current symptoms on the ASRS to be included in the substance use 
only group.  
Although only 23 participants completed the study and were included in the final sample, 
another 14 possible participants were screened. Of those 14 possible participants, 7 met criteria 
and qualified for the study based on the results of their prescreening, but were unable to be 
contacted to complete the study. The other 7 possible participants did not meet criteria for the 
study, based on the results of their prescreening measures. Either they exhibited some attentional 
symptoms during childhood, but did not endorse adequate current symptoms to be included 
(N=4), or they did not endorse childhood attentional symptoms, but endorsed more than two 
current symptoms (N=3). 
All interviewing and data collection occurred individually in a private room at the 
substance abuse agency. Once participants consented to participate, they completed a semi-
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structured research interview with embedded self-report measures. The interviewers were trained 
to conduct these interviews in a standardized fashion providing participants help as needed with 
the self-report measures. All the participants completed the measures in the same specified order 
so as to control for possible questionnaire effects. Specifically, participants first completed a 
demographic/background form, and then a lifetime substance use interview examining ages and 
patterns of use as well as treatment history. (See Appendix B for measures developed for this 
study.) Next, they were asked to fill out self- report measures related to conduct problems 
experienced growing up and their motives for substance use. Lastly, all participants completed 
the Barkley executive functioning measure. For those not reporting ADHD symptoms, the 
interview ended and they were thanked for their time. Those who screened positive for ADHD, 
also completed a further diagnostic interview assessment (CIDI ADHD module) confirming 
ADHD symptoms and addressing their ADHD history and impact of their symptoms. Finally, 
comorbid participants were also asked a few qualitative questions so as to allow them to briefly 
discuss the impact they think their ADHD had on their substance use and the kind of help they 
think individuals with co-occuring ADHD may need within substance abuse treatment. The 
entire interview and evaluation process lasted between half an hour and an hour and a half for all 
participants.   
Measures 
ADHD Screening (WURS/ASRS) 
Wender Utah Rating Scale (WURS) for Attention Deficit Hyperactivity Disorder 
 The Wender Utah Rating Scale (WURS-25) is used to assess childhood Attention Deficit 
Hyperactivity Disorder retrospectively within adults (Ward Wender, & Reimherr, 1993). There 
are a total of 25 questions specifically associated with the ADHD diagnosis answered by the 
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adult participant rating their childhood behavior on a 5-point Likert (0-4) scale. The total score is 
calculated by the sum of the item responses. The recommended cutoff score for this instrument is 
46, and indicates that the participant likely has had ADHD.  
The measure was developed based on a combination of the Utah Criteria and DSM-IV 
criteria, and was created specifically for retrospectively diagnosing ADHD in adults based on 
childhood symptoms (Wender, 1995). The WURS-25 demonstrates excellent psychometric 
properties, and in a recent systematic review of scales used to identify adults with ADHD, it was 
listed as having the best combination of psychometric properties overall compared to other scales 
(Taylor, Deb, & Unwin, 2011), particularly when used in conjunction with the Adult ADHD 
Self-Report Scale-Version 1.1 (Dakwar et al., 2012). Used alone, it has demonstrated high 
internal consistency reliability (r=.86-.92).  In addition, the WURS-25 also was shown to have 
excellent specificity (96%) as well as sensitivity (96%) at the cutoff of 46 (Taylor et al., 2011). 
In the present study, alpha for the WURS using the total sample was .96. 
The Adult ADHD Self-Report Scale—Short Form (ASRS) 
The Adult ADHD Self-Report Scale—Short Form (ASRS) was developed by the World 
Health Organization to assess Attention Deficit Hyperactivity Disorder symptoms within adults. 
The short form has only six items, on which participants rate their current symptoms on a 5-point 
Likert (0-4) scale. If participants endorse 4 of the 6 items with adequate severity, it indicates that 
the participant likely has ADHD. When compared to the longer 18 question version of the 
ASRS, the short version performed better overall in sensitivity (68.7% vs. 56.3%), specificity 
(99.5% vs. 98.3%), and total classification accuracy (97.9% vs. 96.2%) (Kessler et al., 2005). 
Alpha for the six ASRS items was .85. Participants who scored greater than the cutoff score of 
46 on the WURS and endorsed 4 of 6 items with adequate severity on the ASRS were  included 
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in the comorbid ADHD and substance abuse group, although ADHD criteria  were confirmed 
using a structured interview.  
Those patients who scored low on these same measures (WURS-25, ASRS) were eligible 
for the comparison group. As a working guide and based on some research by McCann, Scheele, 
Ward & Roy-Byrne (2000), it was decided that those below a cutoff score of 36 on the WURS, 
and who also did not endorse more than two items of adequate severity on the ASRS be 
considered as not having ADHD symptomatology.  
Substance Abuse History Measures   
Participants were interviewed regarding their substance abuse history, based on a 
modified version of the Drug History Questionnaire (DHQ) (L. C. Sobell, Kwan, & Sobell, 
1995). The DHQ assesses for participant’s lifetime and recent drug use across different drug 
classes including: alcohol, cannabis, stimulants, benzodiazepines/tranquilizers, 
sedatives/hypnotics, opioids, hallucinogens, inhalants, steroids, and illegal use of prescription 
drugs (Sobell et al., 1995). When comparing substance users on their DHQ at two different 
points in time, the significant correlations between these interviews were in the moderate to high 
range (r=.53-.93) with greatest consistency for reporting heroin and narcotics use, and lowest for 
hallucinogens and stimulants (Sobell et al., 1995).  
The DHQ uses cards to help participants accurately recall their drug use, by first sorting 
those substances they have never used from those that they have used at least once. For those 
drugs that they have used once or more, they are asked to indicate those which they have used on 
a frequent or regular basis as opposed to once or twice experimental use.   For those drugs used 
more than once, additional information was collected, including: age at first use, last use, total 
years used, total years of problematic use, frequency in the past 6 months, and route of 
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administration.  Within the interviews, participants were asked about their primary drug of 
choice when it became clear that many of the patients abused opioids, rather than alcohol as we 
initially expected.  In addition, questions were asked about attempts to quit and treatment history. 
The latter questions cover age at first treatment and the number of treatment episodes for alcohol 
and other drugs as well as longest period in treatment and longest period of abstinence. These 
treatment questions were primarily taken from the Addiction Severity Index, a semi-structured 
interview used for treatment planning and evaluation in substance abuse clinics (McLellan, 
Luborsky, Woody, & O'Brien, 1980).  
Conduct Problems Measure  
 In order to assess and control for the possible associated effect of conduct problems 
within this population, all participants were briefly screened for a history of conduct problems in 
childhood and adolescence. There were a total of 15 yes/no questions asked about conduct 
problems, based on the DSM-IV criteria for conduct disorder (American Psychiatric Association, 
2000). These childhood conduct questions were taken from the SCID-II Personality Disorder 
screening instrument and map on to the DSM-IV childhood criteria for antisocial problems.  
Desired Effects of Drinking (DEOD) 
 Based on the idea that those with ADHD may use substances for different motives (ie, 
self-medication, mental effort, coping), we used a modified version of the Desired Effects of 
Drinking (DEOD) Scale to measure different motives for using various substances. This 36-
question self-report scale described by Doyle, et al. (2011) was designed to assess reasons or 
motives for drinking. In addition to measuring respondents motives for drinking, we also asked 
them to rate their motives for using illicit substances, either stimulants, opioids, or marijuana, 
depending on their primary drug of choice and substance history. There are three primary or 
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overarching motives for use that the DEOD measures: coping, social, and enhancement. In 
addition, these factor scores are further broken down into nine subscales measured by four 
questions each. These subscales include: negative feelings, self-esteem, relief, drug effects, 
social facilitation, sexual enhancement, positive feelings, assertion, and mental effects. 
Respondents were asked to consider how often they have used substances to achieve any of these 
desired effects. Each question was rated on a 5-point Likert scale (0=never, 1=sometimes, 
2=often, 3=almost always, 4=always). Although one can obtain a total score for the DEOD 
measure, more emphasis is placed on scores of the three factor scores and individual subscales.  
In a study looking at the DEOD measure within a clinical population seeking treatment 
for their alcohol dependence, the reliability of the three primary subscales was found to be: 
coping motives (r=.78), social motives (r=.83), and enhancement motives (r=.99) (Doyle et al., 
2011). Reliability estimates for each of the nine subscales were moderately good to high. Only 
the drug effects and positive feelings subscales fell below a reliability estimate of .70, with their 
reliabilities measured at .57 and .67 respectively. Considering each of these subscales is 
comprised of only four questions, these may be acceptable values. In the present study, we found 
that for alcohol motives, internal consistency for the entire measure was high (α=.98) as well as 
for each of the three primary factors (coping (α=.97), social (α=.95), and enhancement motives 
(α=.90)).    
Consistent with the literature showing motives are proximally related to substance use, 
when the DEOD was compared to measures of post-treatment alcohol consumption, Doyle et al. 
found that the DEOD total score significantly predicted drinks per drinking day (F1, 441=9.20, 
p=.0026), and percent days abstinent (F1, 559=12.64, p=.0004), where more endorsed motives was 
related to greater alcohol consumption and less abstinence from alcohol (2011).       
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Barkley Deficits in Executive Functioning Scale (B-DEFS)  
 This 91-question self-report scale designed by Barkley and Murphy (2011) is based on 
executive functioning theories (Barkley, 1997) and was specifically tailored to assess tasks of 
executive functioning in adults with ADHD. The scale items focus on problematic symptoms, or 
deficits, rather than on positive or normative executive functioning in the participant’s everyday 
life. Respondents rated the frequency of various behaviors over the last six months, and were 
prompted to consider their typical behavior when not under the influence. There are five 
executive functioning dimensions assessed through a 0–3 Likert scale (0=rarely or not at all, 
1=sometimes, 2=often, and 3=very often) including: self-management to time, self-
organization/problem solving, self-restraint (inhibition), self-motivation, and self-regulation of 
emotions. The self-management to time factor deals with sense of time, time management, 
planning, preparing for deadlines, and other goal-directed behaviors. The self-
organization/problem solving factor focuses on thinking quickly when confronted with 
unexpected events, and to organizing one’s thoughts and actions. The self-restraint or inhibition 
factor deals with making impulsive decisions, and doing things without regard for the 
consequences. The self-motivation factor deals with needing more supervision than others when 
working, getting bored easily, and not doing all of assigned work. Finally, the self-regulation of 
emotions factor focuses on being easily distracted when doing boring work, being able to persist 
at boring activities, and sustained attention.  
 The internal consistency of each B-DEFS subscale was reported as follows: self-
management to time, .95; self-organization/problem solving, .96; self-restraint, .93; self-
motivation, .91; and self-regulation of emotions, .95. The internal consistency for the total 
executive functioning score was .92. Test-retests reliability was assessed after a period of 2-3 
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weeks after initial testing, and found to be .84 for the total scale score, which is quite satisfactory 
given that the scores did not change significantly over this interval (Barkley & Murphy, 2011). 
In this study, we also found the internal consistency of the B-DEFS to be quite high. The alpha 
reliability for the total score was .99, and alphas for the subscales were as follows: self-
management to time, .97; self-organization/problem solving, .96; self-restraint, .95; self-
motivation, .96; and self-regulation of emotions, .95.  
 In terms of validity, this scale has not only demonstrated the ability to discriminate those 
with ADHD from controls, but also is reported to have significant associations with various 
measures of impairment in life activities including: occupational and educational functioning, 
social relationships, driving, and financial management (Barkley & Murphy, 2011). 
Composite International Diagnostic Interview (CIDI) 
The World Health Organization Composite International Diagnostic Interview (CIDI) 
module for ADHD was administered to all participants that screened positive (WURS, ASRS) 
for a history of childhood and current ADHD symptoms in order to confirm that they meet 
ADHD criteria. The CIDI version 3.0 is a fully structured, lay administered interview developed 
by the World Health Organization. The CIDI asks a series of yes-no and symptom frequency 
questions, rather than using more open-ended probes in other instruments. It has been shown to 
be a reliable and valid instrument (Haro, Arbabzadeh-bouchez, Brugha, deGirolamo, Guyer, Jin, 
et.al, 2006). To determine the diagnostic concordance of the CIDI, a general clinical appraisal 
study was carried out with samples in France, Italy, Spain, and the United States. Diagnoses 
were compared using follow-up interviews with the Axis 1 research version of the Structured 
Clinical Interview for DSM-IV (SCID). In addition to the overall reappraisal sample (n=325), 
more focused clinical samples were used to validate several specific CIDI diagnosis, including 
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adult ADHD (n=154). The investigators found moderate to good individual level CIDI-SCID 
concordance for most psychiatric disorders when considering lifetime prevalence. Another 
measure of classification accuracy used in diagnostic studies is the area under the ROC curve as 
this measure is reportedly not influenced by the prevalence of disorders. This statistic was 0.76 
overall for the dichotomous lifetime individual-level classification for the majority of diagnoses 
assessed; for the specific diagnosis of ADHD in adults, the area under the ROC curve statistic 
was substantial at 0.86 (Haro et al., 2006). The CIDI ADHD module was administered via the 
paper version to ADHD and substance abuse participants. Participants were reminded that in 
answering the questions, they should think of themselves when not under the influence and to 
consider periods of time in their life when they have been abstinent from alcohol and other 
drugs.  
Qualitative Questions about ADHD and Substance Use 
Given the exploratory nature of the present study, in addition to the quantitative self-report 
measures, participants classified as having ADHD symptoms were also asked several qualitative 
questions so as to allow them to briefly discuss the relationship they think their ADHD has had 
on substance use. They were also asked open-ended questions about the impact of ADHD 
symptoms on treatment and recovery, and how treatment might better address their specific 
needs. The questions allowed participants to reflect on their experiences, and elaborate on their 
responses. The specific questions included the following: 1) How do you think your difficulties 
with attention have influenced you use of alcohol and/or other drugs? 2) Do you think your 
drinking (or any other drug use) improved, worsened, or had no impact on your ADHD 
symptoms? 3) How do you think your difficulties with attention have influenced your efforts at 
recovery and/or treatment experience(s/success? What was difficult for you? 4) How could 
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alcohol and/or other drug treatment better help individuals with co-occurring attention problems?  
What do you think you need more help with or other suggestions?   
Ethical Issues 
The proposed study included attention to several important ethical issues. These were 
assuring that there was no coercion to participate and obtaining fully informed consent, 
confidentiality considerations, minimizing distress on participants, and protecting them from any 
potential harm. The study was approved by the university Institutional Review Board (IRB) (see 
Appendix A), as well as the agency’s internal research review committee. Participant recruitment 
and the informed consent process and written statement were also specifically approved by the 
IRB. It was explained to potential participants that they did not have to participate and that 
whether or not they participate would not affect their treatment at the agency or access to any 
services. Confidentiality of the information provided in the interviews was assured with the 
exception of imminent risk of harm to self or others. We made every effort to ensure that 
participants’ confidentiality was protected, including having participants’ names only appear on 
the informed consent, and otherwise using a coded ID number thereafter.  
Reporting on psychosocial and/or health related topics, including drug and alcohol use 
and deficits in executive functioning, could conceivably be distressing for a participant. 
However, the risk for this was seen as minimal given participants had entered treatment and the 
study questionnaires have been used many times in prior research. The informed consent 
specified that participants did not have to answer any question they do not wish to answer. 
Moreover, most substance abuse patients actually benefit from telling their story to a concerned 
listener who is encouraging them in their efforts toward recovery. Another related risk 
considered was that of labeling. It was explained to the ADHD participants that the evaluation of 
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their attention and related factors was for the purpose of research and not a clinical diagnosis. 
ADHD participants were encouraged to discuss their attentional problems and possible need for 
further evaluation with their counselor and physician for additional or supplemental treatment 
recommendations.   
Data Analysis 
Data were analyzed using the Statistical Package for the Social Sciences (SPSS for 
Windows, Version 19 SPSS Inc.  The major research questions are related to describing 
associated differences and predicting the likelihood of group membership based on three 
domains: substance use patterns, motives for drinking and stimulant use, and executive 
functioning. Descriptive statistics were used to describe the demographic information for the 
participants as well as for each of the predictor variables within these domains. As this was an 
exploratory study into an area that has not been heavily researched, the groups were initially 
contrasted on variables in each domain. Independent-samples t-tests or chi-square tests were 
used to assess for initial differences, with statistical significance set at p < .05.   
Correlation analyses were performed to examine the associations among measures within 
these domains as well as between significant substance use variables, motives for use subscales, 
and executive functioning subscales. The main research questions were analyzed using binary 
logistic regression analyses to predict likelihood of group membership based on the significant 
associated predictor variables. In order to compare odds ratios among predictors, variable scores 
were standardized.   These analyses were also conducted controlling for conduct disorder 
symptoms, to see if predictors remained significant. 
  
 
CHAPTER 3: RESULTS 
Descriptive Statistics 
The study sample was briefly described under participants in the method section. Table 2 
provides descriptive statistics on the demographic characteristics of the final study sample by 
group. There were 13 participants with ADHD and Substance Abuse and 10 comparison 
participants with Substance Abuse only. The mean age of the sample was 25.5 years (SD = 4.2), 
with the comorbid ADHD group being slightly older (26.4 years) than the substance use only 
group (24.2 years).  
The final sample included more women than men (60.9% vs. 39.1%), and more 
Caucasians than minorities (60.9% vs. 39.1%), but groups did not differ significantly on any 
demographic variables. The average number of years of education was 12 years (SD = 2.6), with 
the comorbid group having on average, slightly more education (12.7 years, SD = 3.1) than the 
substance use only group (11 years, SD = 1.5). Although the majority of the sample was not 
currently enrolled in school (73.9%), more of the substance use only group reported attending 
school either part time (20%) or full time (20%), compared to 7.7% of the ADHD comorbid 
group attending either part time or full time. Interestingly, more of the substance use only group 
had repeated a grade than those with comorbid ADHD (40% vs. 10%), and more of those in the 
ADHD comorbid group had been suspended or expelled from school than their substance use 
only counterparts (92.3% vs. 70%) although the average rate of being suspended or expelled for 
both was high (82.6%). T-tests and Chi squares were used to evaluate these differences. 
However, with the small sample size, none of the demographic contrasts reached statistical 
significance.  
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Table 2. Demographics      
 
Variable 
ADHD+SUD 
(N=13 ) 
SUD Only 
(N=10 ) 
Total Sample 
(N=23) 
Age in years (mean, SD) 26.42 (4.04) 24.20 (4.26) 25.48 (4.20) 
Sex    
     Females 9 (69.2%) 5 (50%) 14 (60.9%) 
     Males 4 (30.8%) 5 (50%) 9 (39.1%) 
Ethnicity    
     Caucasian 9 (69.2%) 5 (50%) 14 (60.9%) 
     Minority status 4 (30.8%) 5 (50%) 9 (39.1%) 
Education in years (mean, SD) 12.69 (3.12) 11.20 (1.48) 12.04 (2.60) 
Marital status    
     Single 5 (38.5%) 8 (80%) 13 (56.5%) 
     Married 3 (23.1%) 1 (10%) 4 (17.4%) 
     Separated/Divorced 3 (23.1%) 0 (0%) 3 (13%) 
     Cohabitating 2 (15.4%) 1 (10%) 3 (13%) 
Current employment status    
     Full time (35+ hours/week) 2 (15.4%) 4 (40%) 6 (26.1%) 
     Part time 3 (23.1%) 1 (10%) 4 (17.4%) 
     Unemployed 8 (61.5%) 5 (50%) 13 (56.5%) 
Enrolled in school    
     Full time student 1 (7.7%) 2 (20%) 3 (13%) 
     Part time student 1 (7.7%) 2 (20%) 3 (13%) 
     Not currently enrolled  11 (84.6%) 6 (60%) 17 (73.9%) 
Repeated a grade 1 (7.7%) 4 (40%) 5 (21.7%) 
Suspended or expelled from school 12 (92.3%) 7 (70%) 19 (82.6%) 
Tables values shown as N (%) unless otherwise specified 
All contrasts are non-significant  
 
 
Group Classification 
Consistent with the literature reviewed above and the intent of this project, participants 
were compared on multiple variables within the domains of substance abuse, motives for 
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substance use and executive functioning and these variables were then used to predict the 
likelihood of group membership as either those with co-occuring ADHD and an alcohol/ other 
substance disorder, or only an alcohol/ other substance use substance disorder. ADHD Status 
(i.e. classification variable) was based on scoring positive on both the Wender questionnaire 
screening for childhood ADHD symptoms and the Adult ADHD Self-Report Scale (ASRS) 
screening for current symptoms; the research diagnosis subsequently was confirmed with the 
CIDI Diagnostic Interview.  In order to confirm that scores on the Wender and ASRS measure 
adequately differentiated the two groups, independent samples t-tests were conducted. 
 
 
 
 
 
Table 3. Group Comparison    
 
Variable 
ADHD+SUD 
(N=13 ) 
SUD Only 
(N= 10) 
Score of Wender Utah Rating Scale 58.23 (11.38) 15.40 (10.21)** 
Score of ASRS 15.77 (2.68) 5.80 (2.53)** 
Conduct disorder items endorsed 3.08 (2.43) .40 (.70)** 
Tables values shown as Mean (SD)  
**Significant at <.01 
 
Table 3 shows average score for the ADHD comorbid group on the Wender Utah rating 
scale were significantly higher than scores of the substance use only group on the same measure 
t(21) = 9.35, p = .000. On the ASRS, scores of those with comorbid ADHD were significantly 
higher than scores of the substance use only group t (21) = 9.05, p = .000.  These results confirm 
that based on prescreening, these groups clearly differed in terms of self-reported childhood and 
current ADHD symptoms.  
The presence of diagnostic criteria for the ADHD group also was confirmed by the use of 
the CIDI ADHD module.  This interview measure confirmed that all 13 participants initially 
identified as meeting the diagnostic criteria for ADHD based on the results of their prescreening, 
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indeed met criteria for ADHD either for inattention, hyperactivity or combined.  Specifically, 
two (15.4%) of the ADHD sample participants reported difficulties primarily with inattention, 
and two (15.4%) of the ADHD sample participants reported difficulties primarily with 
hyperactivity/impulsivity. The remaining nine (69.2%) reported difficulties with both inattention 
and hyperactivity, meeting the research diagnosis of ADHD, combined type. When asked about 
previous diagnosis of ADHD, nine of 13 (69.2%) participants in the ADHD group reported that 
they had been diagnosed with ADHD in the past. Eight of the thirteen had been prescribed 
stimulant medication, but it was unclear if they were taking these medications currently, or had 
only been prescribed them in the past. 
When participants with either primarily inattention or combined type were asked when 
they first noticed symptoms of inattention, they reported on average age 8.55 (SD = 4.03). 
Similarly, those with hyperactivity symptoms recalled that they first noticed these symptoms at 
age 8.08 (SD = 3.15). Participants were asked how much their ADHD symptoms have affected 
them over the past 12 months in various areas on a scale of 0-10, with one indicating no 
interference, and ten being very severe interference.   Overall, participants reported “moderate” 
interference in the following areas, with the most difficulty with chores at home: chores at home 
(M = 6.46, SD = 2.47, N = 13), ability to do well in school or work (M = 6.00, SD = 2.57, N = 
11), ability to get along with family (M = 5.08, SD = 2.66, N = 13), and social life (M = 4.92, SD 
= 2.29, N = 13).  
 In addition, we examined the associated relationship of childhood conduct problems 
which often covary with both ADHD and substance use disorders. There were assessed by the 
listing of 15 specific DSM-IV conduct problems on the SCID PDQ. We found that indeed the 
participants in the combined ADHD and substance use group, endorsed significantly more 
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conduct problems than the substance use only group t(21) = 3.36, p = .003. The scores on the 
SCID PDQ for the ADHD group ranged from 1 to 10, as compared to the substance use only 
group, whose scores only ranged from 0 to 2.  The only conduct problems the substance use only 
group reported were stealing or shoplifting/forging signatures, and running away or staying away 
overnight;  the ADHD and substance use group additionally reported staying out after curfew, 
and starting fights, as well as  stealing or shoplifting/forging signatures, and running away or 
staying away overnight. As a result, as planned, the Conduct problems measure was employed as 
a control variable or covariate in logistic analyses below.   
Research Questions 
The major research questions are related to describing associated differences and 
predicting the likelihood of group membership based on three domains: substance use patterns, 
motives for drinking and stimulant use, and executive functioning. Descriptive statistics for each 
of the associated or predictor variables within these domains are reported including means and 
standard deviations. As this was an exploratory study into an area that has not been heavily 
researched, the groups were contrasted on variables in each domain. Although it is understood 
that the use of multiple tests increases the experiment wise error rate and potentially could lead 
to significant results due to chance, we were interested in identifying possible differences to be 
confirmed in future work given this is a pilot study. However, the overarching research question 
was addressed using hierarchical logistic regression analyses to predict likelihood of group 
membership based on the significant associated predictor variables. 
Research Question #1:  Substance Use Patterns 
In terms of substance abuse and alcohol and drug treatment histories, which variables are 
associated with and predict comorbid ADHD /Alcohol and Other Drug Abuse?  
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Within the domain of substance use history, there were four  broad categories of  possible 
associated  variables including:1) lifetime types of drugs used (including particularly abuse of 
stimulants) 2) total number of substances used and primary drug of choice 3) information about 
specific drug categories used including age of first use, problem use, route of administration (if 
applicable), and quit attempts and 4) treatment history including age of first treatment, number of 
treatments, and longest period in active treatment. More frequent stimulant use/abuse in the 
ADHD/Alcohol and Other Drug Abuse group was hypothesized, along with earlier age of onset 
of substance use.  
Lifetime types of drugs used. Table 4 lists the percentages of participants who reported 
use of the various drugs on the Drug History Questionnaire. A Chi-squared test for independence 
was employed to determine the percentage of participants who reported using various substances 
based on if they were in the ADHD and substance use group or substance use only group. 
Interestingly, every participant reported using both alcohol and marijuana, and nearly every 
participant reported using nicotine. A significant difference between the two groups on 
substances use was only found for all stimulant use. Specifically, while 100% of the ADHD and 
substance use group reported use of illicit stimulants such as cocaine, only 40% of the substance 
use group reported using these substances χ2 (1, N = 23) = 10.53, p = .001. Likewise, although 
nearly 40% of the ADHD and substance use group reported using non-prescribed stimulant 
medication such as Ritalin, none of the substance use only group reported using non-prescription 
stimulants χ2 (1, N = 23) = 4.92, p = .027.  
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Table 4. Percentage of Participants Reporting Use of Various Substance 
 
Variable 
ADHD+SUD 
(N=13 ) 
SUD Only 
(N=10 ) 
Alcohol use 100 100 
Nicotine use 100 90 
Marijuana use 100 100 
Stimulant use (meth, cocaine, etc.)  100 40*** 
Non-prescription stimulant use 38.5 0* 
Benzodiazepine use 76.9 40 
Opiate use 84.6 50 
Inhalant use  38.5 10 
Hallucinogen use 76.9 30 
Sedative/Hypnotic use 7.7 0 
Steroid use 7.7 0 
Tables values shown as N (%)  
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
 
Total number of substances used and primary drug of choice. Table 5 provides data 
on the total number of types of drugs used and the drug of choice of participants. An independent 
samples t-test was utilized to compare the groups in terms of the total number of substances they 
had utilized over their lifetime. Total number of reported substances of those with comorbid 
ADHD was significantly higher than the number of substances reported being used by substance 
use only group t(21) = 3.21, p = .004. To determine the differences between the groups on 
primary drug of choice, a Chi-squared test for independence was employed. The chi-squared 
analysis for primary drug of choice was not significant χ2 (3, N = 23) = 5.64, p = .131, but the 
ADHD and substance use group had a larger percentage whose primary drug of choice was 
opiates.  
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Table 5. Primary Drug of Choice    
 
Variable 
ADHD + SUD 
(N=13 ) 
SUD Only 
(N= 10) 
Total number of substances used, lifetime  8.70 (2.53) 5.20 (2.66)** 
Primary drug of choice (%)    
     Alcohol 0 (0%) 0 (0%) 
     Marijuana 2 (15.4%) 4 (40%) 
     Stimulants  0 (0%) 1 (10%) 
     Opiates  11 (84.6%) 4 (40%) 
     Benzodiazepines  0 (0%) 1 (10%) 
Tables values shown as Mean (SD) unless otherwise specified 
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
 
Use of specific substances. Tables 6-11 provide substance use information for each of 
the specific drug categories. A combination of independent samples t-tests and chi-squared tests 
for were utilized to describe the specific patterns of use for individual substances. Only 
substances that had been frequently utilized by both groups were included in the analysis, 
specifically alcohol, nicotine, marijuana, stimulants (cocaine, meth, etc.), heroin and other 
opioids.  Each substance was analyzed in terms of if the participants of the groups had ever 
utilized the substance, the age of first use, the total number of years used, and the route of 
administration (if applicable). In addition, it was noted if the participant endorsed that use of the 
particular substance was a problem for them, and if it was a problem, the number of years of 
problematic use. Finally, participants reported if they had ever attempted to quit the particular 
substance, and if they had attempted to quit but been unsuccessful, how many times they had 
tried to quit.   
In terms of alcohol use, independent samples t-tests revealed that there were significant 
differences between the groups in terms of age of first use of alcohol, total years using alcohol, 
and number of unsuccessful quit attempts. As hypothesized, the age of first use of alcohol for 
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those with comorbid ADHD was significantly lower than the age of first use reported by the 
substance use only group t(21) = -2.69, p = .014. In addition, the total years using alcohol was 
significantly higher for the comorbid ADHD group than the total years of alcohol use reported 
by substance use only group t(21) = 2.92, p = .008. In addition, although more participants in the 
ADHD group had attempted to quit alcohol in the past (92.3% vs. 70%), the substance use only 
group reported significantly more unsuccessful attempts to quit alcohol than the ADHD and 
substance use group t(21) = -2.38, p = .029.  
 
Table 6. Alcohol Use   
 
Variable 
ADHD + SUD 
(N=13 ) 
SUD Only 
(N= 10) 
Ever used (%)  13 (100%) 10 (100%) 
Age of first use  13.15 (2.19) 15.60 (2.12)* 
Total years used  11.38 (4.74) 5.70 (4.47)** 
Endorsed Problem use (%)  4 (30.8%) 2 (20%) 
       Years of problem use  0.85 (1.57) 0.40 (.84) 
Attempted to quit (%)  12 (92.3%) 7 (70%) 
       Unsuccessful quit attempts  0.00 (0) 0.78 (1.09)*  
Tables values shown as Mean (SD) unless otherwise specified 
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
 
Aside from alcohol variables, significant differences were found between the groups in 
terms of the age of first use for nicotine and marijuana. In terms of nicotine, the age of first use 
of the comorbid ADHD group was significantly lower than the age of first use reported by the 
substance use only group t(20) = -2.63, p = .016.  Results for marijuana were similar, as the age 
of first use of marijuana for the comorbid ADHD group was significantly lower than the age of 
first use reported by the substance use only group t(21) = -2.16, p = .043.  
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Tables 9 through 11 provide the substance use information for stimulant, and opioids 
separating out heroin use. However, there were no significant differences between the groups 
involving these drugs.  
 
Table 7. Nicotine Use   
 
Variable 
ADHD + SUD 
(N=13 ) 
SUD Only 
(N= 9) 
Ever used (%) 13 (100%) 9 (90%) 
Age of first use 12.92 (1.94) 16.33 (4.10)* 
Total years used 10.85 (5.41) 7.92 (4.96) 
Endorsed Problem use (%) 12 (92.3%) 4 (44.4%) 
     Years of problem use 7.80 (6.14) 3.22 (5.59) 
Attempted to quit (%) 11 (84.6%) 5 (55.6%) 
     Unsuccessful quit attempts 2.82 (3.00) 1.60 (2.07) 
Tables values shown Mean (SD) unless otherwise specified 
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
 
 
Table 8. Marijuana Use   
 
Variable 
ADHD + SUD 
(N=13 ) 
SUD Only 
(N= 10) 
Ever used (%) 13 (100%) 10 (100%) 
Age of first use 14.00 (2.20) 16.00 (2.21)* 
Total years used 9.46 (5.68) 6.10 (3.63) 
Endorsed problem use (%) 5 (38.5%) 5 (50%) 
     Years of problem use 3.35 (5.79) 3.10 (4.88) 
Attempted to quit (%) 11 (84.6%) 9 (90%) 
     Unsuccessful quit attempts .64 (1.43) 1.89 (2.47) 
Tables values shown as Mean (SD) unless otherwise specified 
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
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Table 9. Stimulant Use (cocaine, meth, etc.)   
 
Variable 
ADHD + SUD 
(N=13 ) 
SUD Only 
(N= 4) 
Ever used (%) 13 (100%) 4 (40%) 
Age of first use 20.00 (4.23) 18.25 (2.06) 
Total years used 3.35 (3.71) 4.25 (3.86) 
Endorsed problem use (%) 4 (23.1%) 3 (75%) 
     Years of problem use  1.12 (2.81) 3.75 (4.35) 
Route of administration (%)   
     Oral 2 (15.4%) 0 (0%) 
     Nasal 11 (84.6%) 3 (75%) 
     Smoking 3 (23.1%) 1 (25%) 
     IV Injection 4 (30.8%) 0 (0%) 
Attempted to quit (%) 11 (84.6%) 4 (100%) 
     Unsuccessful quit attempts 0.73 (1.68) 1.25 (1.89) 
Tables values shown as Mean (SD) unless otherwise specified 
All contrasts are non-significant 
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Table 10. Heroin Use   
 
Variable 
ADHD + SUD 
(N=8 ) 
SUD Only 
(N= 4) 
Ever used (%) 8 (61.5%) 4 (40%) 
Age of first use 22.13 (4.42) 18.50 (3.11) 
Total years used 4.57 (4.20) 3.33 (3.89) 
Endorsed problem use (%) 7 (87.5%) 2 (50%) 
     Years of problem use 3.75 (4.37) 1.50 (2.38) 
Route of administration (%)   
     Oral 2 (25%) 1 (25%) 
     Nasal 6 (25%) 2 (50%) 
     Smoking 1 (12.5%) 0 (0%) 
     IV Injection  6 (75%) 1 (25%) 
Attempted to quit (%) 8 (100%) 2 (50%) 
     Unsuccessful quit attempts 2.63 (3.42) 2.00 (1.41) 
Tables values shown as Mean (SD) unless otherwise specified 
All contrasts are non-significant  
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Table 11. Opioid use (besides heroin)   
 
Variable 
ADHD + SUD 
(N=11 ) 
SUD Only 
(N= 5) 
Ever used (%) 11 (84.6%) 5 (50%) 
Age of first use 19.91 (4.03) 17.00 (2.00)  
Total years used 5.67 (3.12) 4.25 (4.09) 
Endorsed problem use (%) 10 (90.9%) 4 (80%) 
     Years of problem use 4.50 (3.72) 4.80 (4.08) 
Route of administration (%)   
     Oral 9 (81.8%) 4 (80%) 
     Nasal 7 (63.6%) 2 (40%) 
     Smoking 0 (0%) 0 (0%) 
     IV Injection  5 (45.5%) 1 (20%) 
Attempted to quit (%) 10 (90.9%) 5 (100%) 
     Unsuccessful quit attempts 11.09 (29.61) 1.60 (2.07) 
Tables values shown as Mean (SD) unless otherwise specified 
All contrasts are non-significant  
 
 
Treatment history. Table 12 reports on treatment variables. In terms of treatment 
history, independent sample t-tests again were conducted to determine the differences between 
groups. Surprisingly, the age of first treatment for the ADHD and substance use group was 
higher than that of the substance use only group  but this difference fell short of statistical 
significance, two-tailed t(21) = 1.08, p = .29. Although the ADHD and substance use group 
reported a higher number of treatment episodes specifically for drugs than the substance use only 
group this difference also fell short of statistical significance, two-tailed t(21) = 1.90, p = .071. 
However, within treatment types, there was a statistical difference between the number of 
treatments specifically for drug detox with the ADHD and substance use group (M = 1.00, SD = 
1.23, N = 13) reporting significantly more treatment for drug detox than the substance use only 
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group (M = .11, SD = .33, N = 13), t(20) = 2.11, p = .048. Otherwise, the groups did not differ on 
the number of substance abuse treatments or the longest number of days in treatment.  
 
Table 12. Treatment History    
 
Variable 
ADHD+SUD 
(N=13 ) 
SUD Only 
(N= 10) 
Age of first treatment  21.77 (4.57) 19.90 (3.45) 
Number of treatments for alcohol  0.00 (.00) 0.30 (.675) 
Number of treatments for drugs 4.23 (3.35) 2.10 (1.29) 
       Drug Detox 1.00 (1.23) 0.11 (.33)* 
Longest number of days in active treatment program 392.69 (598.38) 332.10 (540.54) 
Tables values shown as Mean (SD)  
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
 Substance abuse logistic regression. A logistic regression analysis was conducted to 
predict the likelihood of group membership based on substance use variables that were found to 
be significant, including if participants utilized stimulants (cocaine and amphetamines), age of 
first use of alcohol, nicotine, and marijuana, and total number of substances used. A test of the 
full model verses a constant-only model was statistically significant, χ2 (6, N = 22) = 29.77, p < 
.000, indicating that the model was able to distinguish between respondents who were or were 
not included in the ADHD group. The model as a whole explained between 74% (Cox and Snell 
R square) and 100% (Nagelkerke R squared) of the variance in group classification, and correctly 
classified 100% of the cases.  
Table 13 shows the logistic regression coefficient, Wald test, and odds ratio for each of 
the subscales. Employing a .05 criterion of statistical significance, none of the predictors had 
significant partial effects. The strongest predictors of ADHD classification were age that 
participants first used marijuana and nicotine. This indicated that respondents who reported 
earlier first use of nicotine and marijuana were more likely to be in the ADHD group than the 
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substance use only group, controlling for all other factors in the model. 
 
Table 13. Logistic Regression Predicting Group Membership from Standardized Substance 
Use Variables   
 
Predictor  
B SE Wald  P Odds Ratio 
     Stimulant use (cocaine, meth, etc.) -655.21 52018.92 .000 .990 .000 
     Non-prescription stimulant use  21.06 13619.33 .000 .999 14042794.83 
     Total number of substances used, lifetime -91.16 8339.01 .000 .999 .000 
     Age of first use, Nicotine 10.76 22139.99 .000 .991 3.649E+027 
     Age of first use, Alcohol -315.03 24613.48 .000 .991 .000 
     Age of first use, Marijuana 63.46 5413.96 .000 .991 3.835E+067 
All contrasts are non-significant       
Research Question #2: Motives for Substance Use 
In terms of reported motives for substance use, which variables are associated with and 
predict likelihood of comorbid ADHD /Alcohol and Other Drug Abuse? It was  hypothesized 
that young adults with ADHD in addition to substance use disorders would  have a different 
profile for motives for drinking, stimulant and opioid use, and report using alcohol, stimulants, 
and opioids more for coping motives, and particularly have higher scores on the scale “mental 
effects.” 
The major factor scores of the Desired Effects of Drinking (DEOD) questionnaire were 
examined as variables within this domain. The two groups were examined for significant 
differences in factor scores for alcohol use including: 1) coping, 2) social, and 3) enhancement. It 
was expected that individuals with comorbid ADHD might have a different profile of motives for 
substance use with greater coping motives, and particularly report using alcohol or other drugs 
for “mental” effects. Unfortunately, as alcohol was the only substance that the majority of 
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participants within both groups had used, we were only able to compare the groups on their 
alcohol use.  
Table 14 lists the drinking motives scores by group on the DEOD, and independent 
samples t-tests were again conducted. None of the results were significant when the groups were 
compared on either the three factor scores, individual subscales, or total score. Total scores on 
the DEOD for alcohol use among the ADHD and substance use group did not differ significantly 
from total scores of the substance use only group t(21) = .41, p = .68.  In terms of the factor 
scores, coping was found to be the highest primary motive for drinking among both the ADHD 
and substance use as well as the substance use only group but the difference between groups was 
not statistically significant, t(21) = .50, p = .619.  Enhancement and Social motives also did not 
differ. Interestingly, drinking for mental effects was the least endorsed motive although again, 
this was not associated with group membership.  
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Table 14. Desired Effects of Drinking for Alcohol 
 
Variable 
ADHD+SUD 
(N=13 ) 
SUD Only 
(N= 10) 
Assertion 2.53 (3.71) 1.60 (2.32) 
Mental 1.85 (2.08) 2.00 (4.14) 
Drug Effects 4.61 (4.75) 4.10 (6.03) 
Positive Feelings 8.92 (6.05)  7.50 (5.44) 
Negative Feelings  5.08 (4.91) 3.50 (5.13) 
Self-Esteem 4.46 (4.54) 4.1 (6.51) 
Relief 7.38 (5.77) 5.40 (6.31) 
Sexual Enhancement  4.62 (5.59) 4.30 (5.54) 
Social Facilitation  6.77 (5.12) 6.90 (5.78) 
Enhancement Subscale 13.31 (10.39) 11.10 (10.32) 
Coping Subscale 21.54 (18.68)  17.10 (23.53) 
Social Subscale  11.38 (10.36) 11.20 (10.29) 
Total DEOD 46.23 (37.05) 39.40 (42.33) 
Tables values shown as Mean (SD)  
All contrasts are non-significant  
 
 
Beyond looking at differences in these motives for alcohol, additional analyses were 
completed within the ADHD group examining motives across substances (see Table 15) for 
using alcohol, stimulants, and opioids, as unlike the substance use only group, the majority of the 
ADHD group had used stimulants and opioids in addition to alcohol. Differences between the 
motives for use endorsed across these substances among the ADHD participants were examined 
using a repeated measures analysis.  In terms of the factor scores (i.e., enhancement, coping, and 
social subscales) and the total score on the DEOD, there was a significant difference in the extent 
to which ADHD participants endorsed motives for using opiates for both enhancement and 
coping motives. Specifically, participants in the ADHD and substance use group were 
significantly more likely to report using opiates for enhancement motives, than either alcohol or 
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stimulants Wilks’ Lambada = .36, F(2,8) = 7.11, p = .017.  Similar results were found for coping 
motives, where participants in the ADHD group were significantly more likely to report using 
opiates to cope than either alcohol  or stimulants Wilks’ Lambada = 29, F(2,8) = 9.89, p = .007.  
On the total score of the DEOD, participants were significantly more likely to report all motives 
for using opiates than either alcohol or stimulants Wilks’ Lambada = .36, F(2,8) = 7.18, p = .016.     
 
Table 15. Desired Effects of  Use Across Drugs Among ADHD 
Participant Group 
 
 
Variable 
Alcohol 
(N=10) 
Stimulants 
(N=10 ) 
Opiates 
(N= 10) 
Assertion 1.50 (2.51) 2.60 (4.22) 5.70 (6.73) 
Mental 1.00 (1.41) 4.70 (4.85) 9.40 (6.60) 
Drug Effects 2.80 (2.74) 2.70 (3.16) 9.30 (5.44) 
Positive Feelings 7.30 (5.93) 6.80 (6.20) 12.70 (3.53) 
Negative Feelings  3.10 (3.48) 3.70 (4.30) 9.30 (6.13) 
Self-Esteem 3.50 (4.38) 3.50 (4.95) 8.40 (7.30) 
Relief 6.00 (5.87) 4.90 (5.76) 11.50 (5.04) 
Sexual Enhancement  3.50 (4.62) 1.80 (3.29) 6.00 (7.21) 
Social Facilitation  5.60 (4.77) 5.20 (5.12) 8.20 (5.92) 
Enhancement Subscale 9.8 (2.76) 14.10 (4.19) 27.80 (4.76)* 
Coping Subscale 15.40 (4.99) 14.80 (5.61) 38.50 (7.05)* 
Social Subscale  9.10 (3.84) 7.00 (2.51) 14.20 (4.06) 
Total DEOD 34.30 (30.48) 35.90 (37.19) 80.50 (46.77)* 
Tables values shown as Mean (SD)  
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
 
 
In summary, participants with ADHD reported greater motives for opiate use than the 
other two drugs. This may reflect drug of choice in that for the ADHD group, 11 of the 13 
(84.6%) reported opioids as their primary drug of choice.  
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There were no group differences on the motives measure which could only be examined 
by group for alcohol motives. As none of the alcohol motives for use variables were significant, 
a logistic regression analysis was not conducted to predict the likelihood of group membership 
based on motives for use.  
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Research Question #3: Executive Functioning  
In terms of executive functioning, would executive functioning predict likelihood of 
comorbid ADHD /Alcohol and Other Drug Abuse? Specifically, it was hypothesized that those 
with comorbid ADHD would report more problems in the area of executive functioning overall, 
and specifically report more problems with self -management of time and self-
activation/concentration. 
The five subscales of the Barkley Deficits in Executive Functioning Scale (B-DEFS) 
were examined for possible associations with group classification and the total score served as a 
predictor variable of comorbid ADHD and Substance Abuse. The five major dimensions of the 
B-DEFS include: 1) self-management to time, 2) self-organization/problem solving, 3) self-
restraint (inhibition), 4) self-motivation, and 5) self-regulation of emotions. Table 16 lists the 
mean B-DEF scale scores for each group along with normative comparison data from the B-
DEFS manual. 
Based on independent sample t-tests, the participants with comorbid ADHD and 
substance use disorders (N = 13)  had significantly higher scores on all subscales of the B-DEFS  
than scores of participants with only substance use disorders (N = 10); in addition, the comorbid 
ADHD/ Substance abuse group scored higher than the participants from the normative sample.  
The specific contrasts are depicted individually in Table 16. On the self-management to 
time subscale, scores of those with comorbid ADHD were significantly higher than scores of the 
substance use only group t(21) = 3.49, p = .002. For the self-organization/problem solving 
subscale, the scores of those with comorbid ADHD and substance use disorders were 
significantly higher than scores of the substance use only group t(21) = 4.25, p = .000. On self-
restraint or inhibition, scores of those with comorbid ADHD and substance use disorders were 
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significantly higher than scores of the substance use only group t(21) = 8.04, p = .000. For self-
motivation, scores of those with comorbid ADHD were significantly higher than scores of the 
substance use only group t(21) = 2.99, p = .007. For the self-regulation of emotions subscale, 
scores of those with comorbid ADHD were significantly higher than scores of the substance use 
only group t(21) = 4.57, p = .000. Finally, for the total score on the BDEFS, scores of those with 
comorbid ADHD were significantly higher than scores of the substance use only group t(21) = 
5.51, p = .000. 
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Direct logistic regression was performed to assess the likelihood that their responses on 
the BDEFS would distinguish those with comorbid ADHD from those without. Standardized 
scores from the five subscales of the BDEFS were initially included. A test of the full model 
verses a constant-only model was statistically significant, χ2 (5, N = 23) = 31.49, p < .000, 
indicating that the model was able to distinguish between respondents who were or were not 
included in the ADHD group. The model as a whole explained between 75% (Cox and Snell R 
square) and 100% (Nagelkerke R squared) of the variance in group classification, and correctly 
classified 100% of the cases.  
Table 17 shows the logistic regression coefficient, Wald test, and odds ratio for each of 
the subscales. Employing a .05 criterion of statistical significance, none of the predictors had 
significant partial effects. The strongest predictors for attention difficulties were self-restraint or 
inhibition, and self-management to time. This indicated that respondents who reported 
difficulties with self-restraint/inhibition or self-management to time were more likely to be in the 
ADHD group than the substance use only group, controlling for all other factors in the model.  
 
Table 17. Logistic Regression Predicting Group Membership from Barkley 
Deficits in Executive Functioning Subscales  
Predictor  B SE Wald  P Odds Ratio 
Self- management to time 27.85 26653.65 .000 .999 1.249E+12 
Self-organization/problem solving -17.97 17215.52 .000 .999 .000 
Self-restraint (inhibition) 176.74 28892.75 .000 .995 5.711E+076 
Self-motivation -17.18 23215.14 .000 .999 .000 
Self-regulation of emotions  -72.24 15099.55 .000 .996 .000 
All contrasts are non-significant       
 This analysis was also conducted controlling for childhood conduct problems. In addition 
to the five subscales of the BDEFS, the number of conduct disorder items respondents endorsed 
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was also included in block one. A test of the full model verses a constant-only model was 
statistically significant, χ2 (6, N = 23) = 31.49, p < .000, indicating that the full model was able to 
distinguish between respondents who were or were not included in the ADHD group. The model 
as a whole explained between 75% (Cox and Snell R square) and 100% (Nagelkerke R squared) 
of the variance in group classification, and correctly classified 100% of the cases.  
Table 18 shows the logistic regression coefficient, Wald test, and odds ratio for each of 
the predictors in the two blocks. Employing a .05 criterion of statistical significance, the number 
of conduct items endorsed had significant partial effects in block one, but none of the other 
predictors or blocks had significant partial effects. However, block 2 as a whole was able to 
significantly distinguish between respondents who were or who were not included in the ADHD 
group χ2 (5, N = 23) = 13.66, p = .018. Aside from conduct disorder, the strongest predictor of 
group membership again was self-restraint or inhibition. This indicates that the BDEFS still 
distinguished the groups after controlling for conduct problems and that when controlling for all 
other factors in the model, participants who reported more difficulties with inhibition were more 
likely to be in the ADHD group.  
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Table 18. Logistic Regression Predicting Group Membership from Standardized Conduct 
Disorder and  Barkley Deficits in Executive Functioning Subscales 
 
Predictor  
B SE Wald  P Odds Ratio 
Block 1      
     Conduct disorder items endorsed   5.59 2.34 5.72 .017* 268.71 
Block 2      
     Conduct disorder items endorsed  49.72 26964.95 .000 .999 3.908E+21 
     Self- management to time 14.80 130213.38 .000 1.00 2680806.23 
     Self-organization/problem solving -8.54 53445.72 .000 1.00 .000 
     Self-restraint (inhibition) 64.55 131596.18 .000 1.00 1.080E+28 
     Self-motivation -7.57 83598.42 .000 1.00 .001 
     Self-regulation of emotions  -26.13 26834.16 .000 .999 .000 
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
Summary Analyses of Group Prediction 
Prior to running summary logistic regressions, zero-order correlations were computed to 
examine the relationships between the significant predictor variables from each of the domains 
discussed previously. Specifically, childhood conduct disorder problems, significant substance 
use history items (i.e., total number of substances used, stimulant use, and age of first use of 
nicotine, alcohol, and marijuana), as well as the three major subscales of the DEOD 
(enhancement, coping, and social), and the total BDEFS score were analyzed. Use of stimulants 
including cocaine and methamphetamine were positively related to number of conduct disorder 
items endorsed (r = .418, p < .05), and total number of substances used (r = .691, p < .01). Non-
prescription stimulant use was positively related to numbers of substances used (r = .634, p < 
.01). Age of first use of nicotine was negatively related to simulant use (r = -.604, p < .01). Age 
of first use of alcohol was positively related to age of first use of nicotine (r = .663, p < .01). Age 
of first use of marijuana was negatively related to total number of substances used (r = -.424, p < 
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.05), non-prescription simulant use (r = -.514, p < .05), and positively related to age of first use 
of nicotine (r = .641, p < .01) and age of first use of alcohol (r = .707, p < .01).  
The DEOD subscales were interrelated but the DEOD coping subscale for alcohol use 
was also positively related to stimulant use (r = .471, p < .05). Finally, the total score on the 
BDEFS measure of executive functioning was included as many of the BDEFS scales were 
highly correlated to each other. The total score on the BDEFS was positively related to number 
of conduct disorder items endorsed (r = .464, p < .05), as well as stimulant use (r = .454, p < 
.05), and negatively related to age of the first use of nicotine (r = -.533, p < .01), alcohol (r = -
.504, p < .05), and marijuana (r = -.420, p < .05).  
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A hierarchical binary logistic regression analysis was employed to predict the probability 
of group membership based on significant variables discussed above. The predictor variables 
included conduct disorder which was entered into block one, and the total score on the BDEFS 
which was entered into block two. The remaining predictor variables, including number of 
substances used, stimulant use (both cocaine, meth, etc. and non-prescription stimulant use), and 
age of first use of nicotine, alcohol, and marijuana, were entered into block three. As the scores 
on the factor scores of the DEOD were not significant, those were not included in the logistic 
regression analysis. In order to compare odds ratios among predictors, variable scores were 
standardized. A test of the full model verses a constant-only model was statistically significant, 
χ2 (8, N = 22) = 29.77, p < .000, indicating that the full model was able to distinguish between 
respondents who were or were not included in the ADHD group. The model as a whole 
explained between 74% (Cox and Snell R square) and 100% (Nagelkerke R squared) of the 
variance in group classification, and correctly classified 100% of the cases.  
Table 20 shows the logistic regression coefficient, Wald test, and odds ratio for each of 
the predictors in the three blocks. Employing a .05 criterion of statistical significance, the 
number of conduct items endorsed had significant partial effects in block one, but none of the 
other predictors or blocks had significant partial effects. According to block 1, the odds ratio for 
conduct disorder items endorsed indicates that when holding the standardized score of all other 
variables constant, for each additional conduct item endorsed, a participant was 228.46 times 
more likely to be in the ADHD group than in the substance use only group. Although the full 
model analysis of all the variables reliably distinguished between those in the ADHD verses non-
ADHD groups, there were no individual variables beyond reported childhood conduct problems 
identified as significant.  
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Table 20. Logistic Regression Predicting Group Membership from Standardized Conduct 
Disorder, Substance Use, and Deficits in Executive Functioning  
 
Predictor  
B SE Wald  P Odds Ratio 
Block 1      
     Conduct disorder items endorsed   5.43 2.34 5.37 .02* 228.46 
Block 2      
     Conduct disorder items endorsed   1994.55 42734.67 .002 .963 - 
     Total BDEFS score 1333.53 23046.52 .003 .954 - 
Block 3      
     Conduct disorder items endorsed  7.73 10441.34 .000 .999 2272.50 
     Total BDEFS score 19.94 11173.04 .000 .999 458767301.37 
     Stimulant use (cocaine, meth, etc.) 20.96 33920.23 .000 1.000 1263057378 
     Non-prescription stimulant use  16.66 22520.86 .000 .999 17155566.99 
     Total number of substances used, lifetime 14.32 16424.60 .000 .999 1649478.39 
     Age of first use, Nicotine 10.76 22139.99 .000 1.000 46922.57 
     Age of first use, Alcohol -17.88 15283.26 .000 .999 .000 
     Age of first use, Marijuana 9.34 18065.94 .000 1.000 11429.33 
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
 
Finally, a second hierarchical binary logistic regression analysis was employed to predict 
the probability of group membership based on significant variables discussed above, with one 
small change. In order to compare the unique contribution of total score on the BDEFS compared 
to conduct disorder, BDEFS was entered into block one, and conduct disorder was entered into 
block two. As in above analysis, the remaining predictor variables, including number of 
substances used, stimulant use (both cocaine, meth, etc. and non-prescription stimulant use), and 
age of first use of nicotine, alcohol, and marijuana, were entered into block three.  The test of the 
full model verses a constant-only model yielded the same results and was statistically significant, 
χ2 (8, N = 22) = 29.77, p < .000, indicating that the full model was able to distinguish between 
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respondents who were or were not included in the ADHD group. The model as a whole 
explained between 74% (Cox and Snell R square) and 100% (Nagelkerke R squared) of the 
variance in group classification, and correctly classified 100% of the cases.  
Table 21 shows the logistic regression coefficient, Wald test, and odds ratio for each of 
the predictors in the three blocks. Employing a .05 criterion of statistical significance, the total 
score on the BDEFS had significant partial effects in block one, but none of the other predictors 
or blocks had significant partial effects (p = .006). According to block 1, the odds ratio for total 
BDEFS score indicates that when holding the standardized score of all other variables constant, 
for each additional point added to the BDEFS score, a participant was 22.12 times more likely to 
be in the ADHD group than in the substance use only group. Although the full model analysis of 
all the variables reliably distinguished between those in the ADHD verses non-ADHD groups, 
there were no individual variables beyond total score on the BDEFS when entered in block one 
identified as significant, including conduct disorder.  Combined with the above analysis, this 
indicates that both conduct disorder symptoms and BDEFS might be used to distinguish the 
groups. One caveat that might be pointed out is that this clear separation between groups might 
also be somewhat related to the way study participants were selected (high or low on ADHD 
symptoms, rather than including ADHD symptoms as a continuous variable). 
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Table 21. Logistic Regression Predicting Group Membership from Standardized Deficits in 
Executive Functioning, then Conduct Disorder and Substance Use Variables  
 
Predictor  
B SE Wald  P Odds Ratio 
Block 1      
      Total BDEFS score   3.10 1.13 7.50 .006** 22.12 
Block 2      
      Total BDEFS score   1333.53 23046.52 .003 .954 - 
     Conduct disorder items endorsed   1994.55 42734.67 .002 .963 - 
Block 3      
     Total BDEFS score   19.94 11173.04 .000 .999 458767301.37 
     Conduct disorder items endorsed   7.73 10441.34 .000 .999 2272.50 
     Stimulant use (cocaine, meth, etc.) -20.96 33920.23 .000 1.000 .000 
     Non-prescription stimulant use  -16.66 22520.86 .000 .999 .000 
     Total number of substances used, 
lifetime 
14.32 16424.60 .000 .999 1649478.39 
     Age of first use, Nicotine 10.76 22139.99 .000 1.000 46922.57 
     Age of first use, Alcohol -17.88 15283.26 .000 .999 .000 
     Age of first use, Marijuana 9.34 18065.94 .000 1.000 11429.33 
*Significant at <.05, **Significant at <.01, ***Significant at <.001 
Qualitative Analysis 
Qualitative questions about the impact of ADHD on substance use and treatment were 
also analyzed in terms of the major themes. It was thought important to ask these 13 participants 
to describe their own experiences and challenges. Since these questions were exploratory and 
meant to fill a gap in the literature regarding how those with ADHD and comorbid substance use 
disorder might differ from those without ADHD, only the major themes across participants are  
described, particularly as related to explaining the quantitative findings.  
Question 1.  Participants were asked how their difficulties with attention have influenced 
their use of alcohol and other drugs. Nine of the 13 ADHD participants cited using substances to 
achieve certain effects, some related directly to their difficulties with attention, some more 
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indirectly. For instance, several mentioned using marijuana or opioids specifically to “help them 
concentrate,” “slow thought processes down,” “be less restless,” and that “drugs would help 
[them] get things done.” One mentioned that they “took the pills to be able to concentrate better, 
to get homework done. [The pills] cured ability to pay attention.” They also reported using 
substances to more indirectly manage associated symptoms of attentional disorders, such as 
frustration or impatience, one reporting the use of substances rather than prescription 
medications when they “need[ed] something to help deal with feelings and emotions. When 
growing up, I was embarrassed to use medications.”  
However, some of the ADHD participants reported that their use of substances was 
unrelated to their attention difficulties. Specifically, one participant indicated that they “wanted 
to feel better about myself so I used drugs, and I don’t feel it is because of attention problems.” 
They reported that “if feeling restless or frustrated, I felt I needed to use substances to deal with 
it.” Another indicated that they did not believe their substance use was related to their attentional 
difficulties as they reported that they used prescribed medications to manage their attentional 
symptoms, “[I] took Ritalin when 12 to manage symptoms of ADHD such as concentrating 
during school and notes.”  
Question 2. When participants were asked if drinking or drug use improved, worsened, 
or had no impact on their ADHD symptoms, eight of thirteen participants believed that their 
symptoms improved as a result of their drug use. One mentioned that their symptoms “improved 
in a sense. I became less restless and didn’t always have to be on the go. In terms of my attitude, 
it helped me become more tolerable, where otherwise I may have become angry more easily.” 
Several participants mentioned specific substances they used to help manage their symptoms. 
Specifically, two participants mentioned using marijuana saying, “Marijuana helps calm my 
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nerves. I would be more relaxed, helps me be less impulsive,” and “I think using marijuana 
helped manage my symptoms, but I don’t think other drug use made a difference.” Others 
mentioned that they used alcohol or opioids to manage their symptoms, and reported that they 
“felt opioids helped me concentrate better,” and that when they used “heroin and opiates, [they 
were] more motivated to get things done, and was more aware of things.” Another indicated that 
although their symptoms improved, there were unintended consequences, reporting “opiated 
helped concentration, but got to the point I looked for them all day so I wouldn’t run out. I 
wasn’t getting anything accomplished.” Another participant mentioned that “drugs seemed to 
help with symptoms. Specifically the depressants, alcohol and opioids helped calm me down and 
lessen ADHD symptoms. Heroin did what I needed it to—it curbed my overthinking, my anger, 
and made me less depressed, allowed me to work and focus on what I needed to do.” 
Three of the participants reported that their attentional symptoms worsened with the use 
of drugs. They reported that when using, they had “difficulty concentrating,” “procrastinated 
more and had more difficulty completing tasks,” and that “when high I became more impulsive.” 
Two participants indicated that they believed there was no impact of their substance use on their 
attentional symptoms.  
Question 3. Participants were asked if they believed that their difficulties with attention 
have influenced their efforts at recovery from alcohol and other drugs. Two of the participants 
felt that their difficulties with attention did not influence them significantly, if at all, one 
mentioning that they “have to read stuff over and over, but that’s okay.” However, the remainder 
of participants (84.6%) mentioned that their difficulties with attention influence their efforts 
towards recovery in a multitude of ways, both short-term and long-term.  
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Several participants mentioned symptoms of ADHD negatively impacting their ability to 
attend and participate in groups and other recovery related activities, such as having “trouble 
remembering appointments, and I forget to do things,” and reporting “difficulty going to groups 
because I am late or don’t show up.” Several participants mentioned underlying self-medication 
of symptoms hindering recovery efforts, one participant mentioned that “this is the first time I’ve 
sought treatment for ADHD symptoms from the doctors, every other time I was self-
medicating.”  “So my recovery was unstable and unsustainable because I kept going back to 
heroin to manage my symptoms.” Another mentioned that “…using alcohol, marijuana, and 
heroin seemed to calm me down. Those have been my coping skills for years, and it’s hard to 
change the habit.” 
Another theme participants discussed was the influence of their attentional symptoms on 
their ability to achieve a long-term goal such as recovery from substance abuse. They reported 
frustration and fear that they “wouldn’t succeed” and that they felt that because of their 
symptoms they “didn’t want to try, no point in continuing.” Additionally, they mentioned that 
“attention difficulties inhibit recovery. Concentrating, forming, and sticking to plans was 
difficult.” One participant mentioned that because of their symptoms, they felt they were “all 
over the place,” and have a “hard time putting forth all effort toward goals.” There is a “lack of 
focus and discipline and I don’t feel like I have the ability and something will always be wrong 
with me.” Another cited impatience and frustration playing a role in relapses, specifically, 
“frustration lead to relapses… hard to keep clean because of impatience.”  
Question 4. Participants were asked how they felt their difficulties with attention have 
affected their progress in treatment and getting the most out of treatment. Almost all of the 
participants (92.3%) cited specific attentional symptoms or the importance of personal 
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motivation to stay focused in treatment on a day to day basis, as well as working towards a long-
term goal. Eight of the participants specifically reported difficulty with paying attention during 
groups and difficulties with “daydreaming,’ “staying focused,” or “get bored and distracted 
easily.” One mentioned that “It’s really hard to keep on task during group. We got off easily onto 
tangents... It’s hard to be in the now—when in group, [I’m] thinking about break. When on 
break, [I’m] thinking about group.” They also reported problems with comprehension due to 
inattention, such as “I do not comprehend info told to me, and I tire easily of hearing the same 
things.”  
Symptoms of restlessness, inattention, and impulsivity were also related to difficulties 
with staying in treatment long term. As one participant reported, difficulties with attention have 
“made me relapse a lot, and not take treatment as seriously as I should.” Other participants 
expressed similar sentiments, including “impulsivity, restlessness influence ability to stay in 
treatment through completion,” and “If something is not fun or enjoyable, I move on to feed the 
void.” Several participants highlighted the importance of personal motivation to be successful in 
treatment, saying “they have to want it first. Everyone goes through recovery differently,” and 
highlighting the skills necessary to succeed long term, “have to devote your time and attention to 
stay in treatment and meet goal.” 
Question 5. When asked how alcohol and drug treatment could better help individuals 
with co-occurring attention problems, many participants gave insightful answers on how 
treatment centers could better help address attentional challenges that influence substance use 
and recovery efforts including prescreening, medication, and external motivators. Several 
participants mentioned the utility of pre-screening for attention problems and following up with 
the results, in order to more fully address these concerns in treatment. One participant mentioned 
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that they had gained insight into their symptoms through the research process, and that they 
“never thought it was that bad, I should talk to someone about [my] ADHD.” Another reported 
that they “believe if ADHD is treated, it would decrease the urge to use substances.”  
Several participants noted the role of medication in treatment of ADHD symptoms. 
However, an expressed concern was that their physician would not prescribe medications for 
their attentional symptoms due to their history of substance abuse. One mentioned that “taking 
ADHD meds would help, but [I have a] hard time talking to my doctor because [stimulant 
medication is] a controlled substance that’s abused.” Another highlighted the importance of 
medication in treatment saying, “First, you gotta get the medication right. I’ve tried different 
things, and none of them worked. Also, being labeled “addicts,” it’s hard to talk to the doctor 
because they think you are pill seeking. It’s a tough situation to be able to talk to the doctors 
about what we need, because sometimes we do know what works, but they don’t want to give it 
to us.” One reported that although they have a previous diagnosis of ADHD, they have had 
difficulty getting medication to treat their symptoms due to their substance use history, “[my] 
new doctor said they won’t prescribe stimulants to substance abusers.”  
Finally, participants mentioned structure and external motivators can often be beneficial 
in treatment. Several mentioned the importance of addressing the comorbid diagnosis through 
groups specifically aimed at helping comorbid ADHD and substance use, teaching coping skills 
and “helping them organize their treatment and stay on top of it.” Another mentioned the 
importance of being sensitive to those with ADHD within groups, and the importance of taking 
breaks to allow time to refocus, particularly during longer groups. Others mentioned the utility of 
external motivators such as “being on contracts for clean drug screens and keeping all 
 84 
 
appointments.” One mentioned that they needed even stronger external motivators, such as 
“being forced to be in treatment helps, wouldn’t commit otherwise.”    
  
 
CHAPTER 5: DISCUSSION 
Major Findings 
        The argument presented in this thesis has been that although studies of ADHD within 
substance abuse populations have indicated a prevalence of approximately 20%, (van Emmerik-
van Oortmerssen et al., 2012), relatively little research has been conducted  to flush out the 
differences between those with ADHD and those without ADHD in substance use treatment 
programs.  It was argued that this work is important because such differences would have 
implications for understanding the development of addictive behavior problems among those 
with ADHD and improving treatment in this subpopulation of individuals with substance use 
disorders (Arias et al., 2008; Faraone, Wilens, Petty, Antshel, Spencer, & Biederman, 2007; 
Wilens, 2004b). 
The major finding from this study was that substance use patients with a history and current 
ADHD symptomology are indeed a separate population with documented clinical differences.  
The use of the Wender and brief ASRS was effective in identifying participants meeting research 
criteria for ADHD as confirmed by the CIDI interview. Moreover even with a very small sample 
size, they were clearly separable not only in terms of reported difficulties in attention but by both 
their history of conduct disorder problems in childhood and the level and severity of  current 
executive functioning deficits. There were also some documented differences in substance use 
history including age of onset of initial drug use and number of drugs abused. It was more 
difficult to show any differences in motives for substance use and the impact on treatment and 
recovery efforts.  
This discussion section will review the major study findings by research question and then 
discuss study limitations, and clinical and research implications of this work.  Areas of 
 86 
 
agreement with the existing literature reviewed above will be highlighted and any inconsistencies 
also noted. The qualitative findings from the comments of ADHD participants are integrated 
throughout and discussed in the relevant section (e.g., effect of use on their ADHD with 
substance use motives, impact on treatment under treatment section).  
Study Plan and Final Sample 
The primary goal of this study was to further expand the literature on co-occurring ADHD 
and Substance Abuse Disorders by examining potential differences in substance use history and 
treatment variables, reported motives for using various substances, and differences in executive 
functioning between a comorbid and substance abuse comparison group. Working with the staff 
at PORT Human Services outpatient substance abuse treatment program, we were able to screen 
and identify 13 individuals with co-occurring ADHD and substance abuse and a comparison 
group composed of 10 individuals in treatment for substance use without this comorbidity over a 
period of three months.  
A total of 37 potential participants were screened for inclusion in the study. Beyond the final 
23 participants included, there were 14 more screened who either did not meet qualifications for 
the study, or did not complete additional measures beyond the prescreening instrument. It 
appears that the use of the Wender and ASRS was effective in identifying participants with both 
current and childhood symptoms, as well as those without any difficulties with attention. Seven 
of the potential participants were excluded due to meeting the threshold for either childhood, or 
adulthood symptoms, but not both. This is important; due to the interconnection between 
substance use and executive functioning, we wanted to ensure that our participants truly had a 
history of ADHD, and that their symptoms were not a function of their substance use. 
Unfortunately, there were seven potential participants who qualified for the study, but were 
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unable to be scheduled for a follow up visit. This is not surprising given the challenges 
associated with no show rates within outpatient substance use treatment, particularly since many 
of these potential participants qualified for the ADHD comorbid group.   
Analysis of Table 3 clearly showed the effectiveness of the Wender/ASRS as a brief 
screener, as there were significant differences between the two groups in terms of their scores on 
both measures. In addition, for those that qualified for the ADHD and substance use comorbid 
group, there was 100% confirmation of a research diagnosis of ADHD using CIDI ADHD 
module. In fact, of the 13 participants, nine reported receiving a diagnosis of ADHD in the past, 
which is higher than expected based on previous research that suggested that many of the 
participants who screened positive for ADHD had not received a diagnosis (Kessler et al., 2006), 
but this may be due to self-selection bias. Eight of the thirteen had been prescribed stimulant 
medication for ADHD in the past, but based on the questionnaire, it was unclear if they are 
currently taking medication to treat their ADHD symptoms, or this was primarily during 
childhood. One of the participants even reported that they had been prescribed medication, but 
had never taken them. 
ADHD and Conduct Disorder 
One challenge associated with conducting research in a substance use population with 
possible ADHD is the high comorbidity of conduct disorder with both ADHD and substance use. 
The literature is mixed regarding the specific independent contribution of ADHD to substance 
use disorders—some report that the effects of ADHD are not as significant when controlling for 
CD (Flory & Lynam, 2003; Torok, Darke, & Kaye, 2012), others suggest that CD might be a 
mediating factor between ADHD and SUD (Mirza & Bukstein, 2011), while others propose that 
ADHD is an independent predictor of substance use disorders (Elkins, McGue, & Iacono, 2007; 
 88 
 
Wilens et al., 2011). It is precisely because of the challenges disentangling the individual effects 
of substance use, ADHD, and conduct disorder that we wanted to be able to assess and control 
for any possible effects of conduct disorder. While we did not test for the specific relationship 
between SUD, ADHD, and CD, we did find that the ADHD group had significantly more 
problems with conduct behaviors during childhood and adolescence. The most frequently 
reported conduct problems during childhood and adolescence were: stealing or shoplifting 
/forging signatures, and running away or staying away overnight, which were reported by both 
groups.  In addition, staying out after curfew, and starting fights were also commonly endorsed 
but only in the ADHD group.   
Given these differences between the groups, we statistically examined whether variables 
contributed to classification beyond conduct disorder in regressions. We found that the presence 
of conduct disorder may predict a large amount of the variance between the groups, but is not the 
only variable that can reliably distinguish the two groups. Based on these results, it is clear that 
regardless of the specific role conduct disorder plays when combined with ADHD and substance 
use disorders, it is important to address conduct problems in addition to ADHD while in 
treatment for substance use disorders. Past research has suggested that patients with the 
additional co-occurring diagnosis of conduct disorder along with ADHD have been found to 
have the poorest outcomes in terms of their long-term course of substance abuse (Wilens et al., 
2011). Future research will need to disentangle the specific differences between these groups, in 
order to allow for the development of targeted treatment plans. 
Substance Use History 
Based on a review of previous literature conducted in the area of substance use history, 
we hypothesized that individuals with comorbid ADHD would differ from those with only 
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substance use disorders in several ways. Specifically we hypothesized that those with ADHD 
would use of more substances overall, both licit (including nicotine), and illicit (including 
stimulants), initiate alcohol and other drug use at an earlier age, and have problems with alcohol 
earlier and for a longer period of time. While we found that those with ADHD did have a 
different substance profile including the use of more substances and initiation of these substances 
at an earlier age, and also used alcohol for a longer period of time, we did not find any 
significant differences between the groups in terms of the duration of their problems. 
Lifetime types of drugs used.  In terms of different substances that each group reported 
using at least once throughout their lifetime, we found that the groups significantly differed on 
the use of stimulant use, both illicit use of cocaine and meth as well as non-prescription 
stimulants such as Ritalin. The groups did not differ on their use of alcohol, nicotine, or 
marijuana, but the ADHD group reported using other illicit drugs including benzodiazepines, 
opiates, inhalants, and hallucinogens. This fits our hypothesis that those with ADHD will have 
used more illicit substances than the comorbid group, but there was not a significant difference 
between the two groups in terms of their use of licit substances (e.g. alcohol or nicotine). This 
makes sense given that previous literature in this area that suggests that subjects with ADHD 
were not more likely than controls to have tried alcohol, cigarettes, or marijuana, but they were 
three times more likely to have used other illicit drugs including inhalants, hallucinogens, 
cocaine, and/or non-prescribed stimulants (Molina & Pelham, 2003).   
Total number of substances and primary drug of choice. Given the wider variety of 
substances tried in the ADHD group, it makes sense that the total number of substances used by 
the ADHD group would be significantly higher than the total number of substances used by the 
substance use only group. When asked about their primary drug of choice, it was somewhat 
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surprising that none of the participants in the ADHD group indicated the preference for 
stimulants, but the majority reported preferring to use opiates. This finding was particularly 
interesting given the differences in use motives for different drugs, and the varied motives 
participants in the ADHD group reported for use of opiates.  
Age of onset of substance use. When the groups were compared on use of individual 
substances, the most significant findings related to the age of first consumption of alcohol, 
nicotine, and marijuana. Specifically, as we hypothesized, those in the ADHD group were 
significantly more likely to start using these substances at an earlier age and for a longer period 
of time than their counterparts in the substance use only group, and on average reported starting 
to use all three of these substance before the age of 14, and endorsed a significant difference in 
terms of length of time they had been using alcohol—over 11 years as compared to 5 years in the 
substance use only group.   
These results are consistent with the literature that suggests that those with ADHD have 
an earlier age of first substance use (Arias et al., 2008), particularly alcohol (Schubiner et al., 
2000). This is important, as research suggests that those who start drinking before age 14 are 
more likely to develop alcohol dependence when compared to those that start drinking at age 21 
(Hingson et al., 2006), and adolescents who have problematic use of alcohol are more likely to 
develop alcohol dependence and other substance use disorders (Rohde et al., 2001). This is also 
interesting given that our participants reported using alcohol for a significantly longer time than 
their counterparts without ADHD.  
One study that looked at patients addicted to multiple substances found that those with 
ADHD had a significantly lower age of first consumption of marijuana, amphetamines, cocaine, 
and heroin compared to those without ADHD (Ohlemeier et al., 2008). Our findings for age of 
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consumption of different substances were similar, with those with comorbid ADHD having a 
significantly younger age of use of alcohol, nicotine, and marijuana. However, we did not find 
statistically significant results for age of first use of cocaine and heroin. 
Substance variables summary. In order to test the hypothesis that substance use 
variables could reliably distinguish between the ADHD group and substance use only group, we 
entered the substance use variables found to have the most significant effects into a logistic 
regression analysis. While none of the variables on their own was found to be have significant 
partial effects in this analysis, as a whole, these variables were able to explain between 74-100% 
of the variance in group classification, and correctly classified 100% of cases, suggesting that 
these variables can reliably differentiate the groups. Based on the odds ratios, the strongest 
predictors of ADHD classification were the age of first use of marijuana and nicotine, along with 
the use of non-prescription stimulant medication. It is somewhat surprising given previous 
literature that age of first use of marijuana and nicotine emerged among the strongest predictors, 
but not the age of first use of alcohol. Future research may want to include age of initiation of 
nicotine and marijuana in addition to alcohol in future analysis.  
Motives for Substance Use  
Research suggests that expectancies and motives are central to alcohol and other drug 
use, and some motives are associated with poorer outcomes (Cooper, 1994; Cox & Klinger, 
1988; Doyle, Donovan & Simpson, 2011; Kuntsche, Knibbe, Gmel, & Engels, 2005); therefore, 
it is important to understand and address motives for use in treatment (Doyle et al., 2011). We 
hypothesized that those with comorbid ADHD would have a different profile for use of alcohol, 
and other drugs, specifically we hypothesized that they would report using these substances for 
coping motives, especially to achieve “mental” effects. Unfortunately, not enough of the 
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substance use only group had utilized stimulants or opioids to compare the two groups on these 
substances, so we were only able to compare the ADHD and substance use only group on their 
alcohol expectancies. However, we were able to compare the ADHD group on the different 
motives for use they reported for each substance—alcohol, stimulants, and opioids. 
 Contrary to our hypothesis, a comparison of the two groups on their motives for use of 
alcohol yielded no significant differences between the groups. These non-significant results 
could be due to the small sample size, the large differences in the standard deviation, or a 
nonsignificant effect. They could also be due to the fact than not all of the participants felt that 
they abused alcohol, or the fact that none of the participants indicated that alcohol was their 
primary substance of choice.  
Although not significantly different between groups as predicted, coping was the highest 
motive endorsed by both groups. Other scales that were elevated corroborate research done by 
Hides (2008) which examined substance use motives in young adults seeking mental health 
treatment. They found that individual subscales including positive and negative drug effects, 
social reasons, and coping are the most common reasons for use (Hides, 2008). Coping motives 
for use may be particularly problematic in this population, as these prior findings suggested for 
those with current substance use disorders, using substances for coping and drug effects were 
related to more severe symptoms and lower levels of functioning (Hides et al., 2008).  While we 
expected the ADHD group to endorse more use of alcohol for coping motives, both groups may 
be using alcohol to cope with various stressors, perhaps not just symptoms of attention as 
initially hypothesized. Interestingly, using alcohol for “mental effects” was the lowest individual 
motive endorsed for both groups, which is contrary to our hypothesis. This may be due to the 
ADHD group possibly using other substances (such as stimulants or opioids) for mental effects, 
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as alcohol was significantly lower than the use of stimulants or opioids when comparing mental 
effects across the ADHD group.   
In the ADHD literature, the primary focus in terms of motives for use or expectancies has 
been on self-medication as a type of coping motive (Blume, Marlatt, & Schmaling, 2000; 
Wilens; 2004). The “self-medication hypothesis” was originally based on the work of Khantzian 
(1997), suggesting that those with psychiatric disorders, including ADHD, report choosing 
specific substances for their compensatory actions, such as those with ADHD symptoms 
choosing amphetamines due to their stimulating properties. However, within the general 
substance use disorders literature, the “self-medication hypothesis” provides conflicting results, 
as certain substances may worsen symptoms, rather than provide relief. When the participants 
with ADHD were asked if their use of substances tend to improve, worsen, or have no impact on 
their ADHD symptoms, the majority reported that their ADHD symptoms were improved by 
using substances such as marijuana, alcohol, and opioids to help them achieve different effects. 
None of them mentioned using stimulant medications to achieve these effects, which is contrary 
to what is widely believed according to the narrow “self-medication hypothesis” for ADHD.  
Additionally, when asked if their difficulties with attention have influenced their use of 
alcohol or other drugs, the majority cited using substances, particularly opioids, to achieve 
specific effects. Many of these desired effects were directly related to their ADHD symptoms, 
including helping them concentrate, slow thought processes down, be less restless, and 
accomplish tasks, suggesting that they used the substances because they believed or expected 
that they would achieve certain results. Although research suggests that certain substances may 
worsen psychiatric symptoms, our participants may believe that their symptoms are being 
lessened by the use of substances—at least initially. Previous literature confirms this 
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phenomenon, which suggests that perhaps the patient believes that substances are, at least 
intermittently, reducing or alleviating their psychiatric symptoms (Blume et al., 2000).  
When the ADHD group was compared on their use of alcohol, stimulants, and opioids for 
achieving different effects, opioids in general were the highest endorsed substance across 
multiple motives. Specifically, opioids were reported to be used significantly more than either 
alcohol or stimulants for all motives other than social facilitation and social subscale. Based on 
our hypothesis, we expected that the ADHD group would highly endorse coping motives and 
using substances for mental effects.  Although we found the coping subscale to be the highest of 
the three subscales, particularly for use of opiates, surprisingly use of substances for mental 
effects within the ADHD group was among the least frequently endorsed motives.  
Overall, it appears that participants in the ADHD group had more and varied motives for 
using opiates than either alcohol or stimulants. This may be related to the higher percentage of 
the ADHD group who endorsed opiates as their primary drug of choice, or the possible belief 
that opiates can help manage their symptoms. It is also likely that as severity of drug use 
increases, endorsement of all motives across the board may increase. Although we did not 
attempt to classify participants’ drug use on the basis of severity, it could be that that the 
endorsement of more motives for opiates reflects greater severity. Regardless, there is a lack of 
research on the use of opioids by those with ADHD, as most research has assumed that 
stimulants are utilized to manage symptoms. Based on our analysis of the motives for use and the 
qualitative discussions, it might be beneficial to further research motives for multiple substances 
and the role they play in “managing” ADHD symptoms.  
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Differences in Executive Functioning  
It has been postulated that the primary deficit in ADHD involves difficulties with 
executive functioning (Barkley, 1997), as adults with ADHD report difficulties such as “feeling 
scattered and being chronically late for appointments, anxious, irritable, and overwhelmed with 
the tasks of daily living” (Elliott, 2002, p. 737).  
Although executive functioning deficits are often associated with ADHD, they are also a 
concern among substance abuse patients. In the field of substance use, there is consistent 
evidence that various substances have a negative impact on executive functioning such as  
attention, learning, memory, and visual spatial abilities, and may be strongly associated with 
impulsivity, working memory, and decision-making (Yücel, Lubman, Solowij, & Brewer, 2007). 
However, it is unclear which comes first—the preexisting deficits in executive functioning, or 
the substance use. Research suggests that preexisting deficits in executive functioning may 
predispose some individuals to substance use disorders, which in turn may exacerbate their 
deficits in executive functioning (Giancola & Tarter, 1999; Nigg et al., 2004). Thus, looking at 
the influence of executive functioning deficits in ability to function is doubly important in those 
with both ADHD and substance abuse. We hypothesized that those with comorbid ADHD would 
report greater deficits in executive functioning compared to the substance use only group, 
particularly for the areas of self-management to time and self-activation/concentration.   
When comparing those with ADHD and substance abuse to those with substance abuse 
alone, there were significant differences found between the groups for every subscale on the 
BDEFS as well as the total score. This was somewhat surprising based on our hypothesis, 
because the significant differences between the groups occurred in each domain of executive 
functioning —not just self-management to time and self-concentration. However, this may 
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reflect less independence of the different aspects of executive functioning and that the BDEFS 
actually measures one factor, since we found the scales to be highly correlated. The BDEFS total 
score significantly predicted group membership along with childhood conduct disorder 
problems.  
Although those with ADHD reported more difficulties with executive functioning 
compared to the substance use only group, it is interesting that the present comorbid ADHD 
group reported more difficulties with executive functioning across the board than either 
Barkley’s normative ADHD or community sample, and even the substance use only group 
reported more difficulties with self-organization/problem solving and self-motivation than 
Barkley’s normative community sample. This suggests that there are perhaps additive effects of 
both ADHD and substance abuse on deficits in executive functioning, above those of ADHD in a 
normative sample alone. This makes sense given that research has suggested that executive 
functioning deficits are present in substance abuse populations as well as within ADHD 
populations. This may also suggest that substance use alone may influence impairments in 
executive functioning.  
Based on the logistic regression examining the influence of the individual BDEFS 
subscales with and without conduct disorder included, self-restraint/inhibition was the most 
predictive factor for membership in the ADHD group. Although we had not hypothesized this 
finding, it makes sense given that inhibition and impulsivity have been associated with other 
problems such as conduct disorder and substance use disorders (White et al., 1999). Self-
management to time was another predictive factor, which we had hypothesized would be an area 
in which the ADHD group would report more difficulties. These results fit together well with our 
qualitative findings, based on participants’ reflection of how their symptoms have influenced 
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them in both treatment and recovery as themes of problems with impulsivity, time management, 
and concentration emerged.  
When participants with ADHD were asked how their difficulties with attention have 
influenced their attempts in treatment and recovery from substances, many noted difficulties 
associated with executive functioning such missing or forgetting appointments, being late, or 
difficulties paying attention when they attend group such as daydreaming, getting bored or 
distracted easily, and not being focused on the group.  These symptoms such as restlessness, 
inattention, and impulsivity were not only reported to be problematic in the short term, but also 
problematic when trying to achieve longer term goals, such as successful completion of 
treatment and maintaining abstinence.  
 Treatment History and Impact on Treatment 
It is important to understand how to manage ADHD symptoms in addition to substance 
use due to the negative impact ADHD may have on the treatment and recovery process of those 
with ADHD and comorbid substance use disorders (Carroll & Rounsaville, 1993). One step in 
trying to understand how to best manage symptoms is to understand the patterns related to 
treatment history. We hypothesized that those with ADHD would report an earlier first age of 
treatment for substance use disorders with more unsuccessful attempts to quit drinking.   
For age of first treatment, our results were not significant between the two groups, but the 
ADHD group surprisingly had a higher average age of first treatment than the substance use only 
group, which was contrary to our hypothesis. However, those in the ADHD group reported a 
larger number of previous treatments for drug use which we had expected, although this number 
was not significant when compared to the substance use only group. The only significant finding 
in the treatment variables was the number of times those with ADHD had been to treatment 
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specifically to detox from drugs. Previous research of cocaine abusers in treatment, those with 
childhood ADHD were younger at presentation for treatment and reported more severe substance 
use, as well as more previous treatment/higher rates of relapse after successful treatment (Carroll 
& Roundsaville, 1993). Although our age of treatment results were the opposite of this study, we 
did find similar results in terms of more previous treatment attempts in the ADHD group.  
When comparing the groups on number of days in treatment, those in the ADHD group 
had a longer average number of days in treatment, but this result was not statistically significant 
compared to the substance use only group. This is similar to the results of study that examined 
the length of stay in a residential treatment center, the mean number of days in treatment was 
lower in ADHD group, but this result was also not statistically significant (McAweeney et al., 
2010).  
Previous research all suggests that those with ADHD may struggle with poorer treatment 
adherence, difficulty with achieving the goals set in treatment, and higher rates of relapse upon 
leaving substance abuse treatment due to attentional difficulties and poor executive functioning 
associated with the disorder (Arias et al, 2008; Carroll & Rounseville, 1993; Ohlemeier et al., 
2008; & Wise, Cuffe, & Fischer, 2001. Unfortunately, in our sample, we were unable to find any 
major differences between the two groups in terms of treatment variables. Both groups had 
similar number of days in treatment, and although the ADHD group had more attempts at 
treatment for drugs, this result was non-significant except concerning the number of times the 
ADHD group had attended detox for their drug use.  
However, the qualitative interviews did suggest potential impact of ADHD on treatment. 
Specifically, participants indicated that they had difficulty with inattention, restlessness, and 
impulsivity which influenced staying on task in groups and maintaining motivation for recovery.  
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They suggested implementing screenings for ADHD symptoms, addressing symptoms through 
medication, increased structure, and external motivators would all be helpful for those struggling 
with ADHD symptoms within treatment for substance abuse. This suggests that treatment may 
be more difficult for some than others. This may be due to symptoms of ADHD influencing their 
ability to concentrate and achieve goals when in treatment, and rates of relapse from treatment.  
Based on the literature and our results, it is not clear if those with comorbid ADHD have 
are less successful than their peers in treatment, but it is clear that there is need for further 
examination of these variables, particularly as they may be related to factors that could influence 
treatment success such as deficits in executive functioning skills generally as well as how to 
manage self-restraint/inhibition and self-management to time specifically.   
Study Limitations  
There are several limitations to this pilot study. The most significant limitation is the 
small sample size. Although we found some suggestive findings, particularly related to 
differences between the two groups in age of first use of several substances, it may be that we 
failed to detect other differences in substance use patterns, and we were unable to examine group 
differences in motives for different drugs of abuse. Relatedly, we also had some attrition in the 
screening process. Due to the time constraints of our participants, we chose to proceed with the 
informed consent and prescreening, and if they qualified for the study we gave the participants 
the option to complete the remainder of the measures at another time. As a result, we had some 
potential participants that qualified for the study, but did not complete the remainder of the 
measures. It is unclear if these potential participants differed from the other participants in key 
ways such as severity of executive functioning.  
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Generalizability is of course limited by age and recruiting participants from a specific 
treatment program within a single community. The stringent inclusion and exclusion criteria, and 
specifically the need for participants to have 30 days of abstinence before participation, may also 
limit generalizability, as it is not known if a group that is able to achieve at least 30 days of 
abstinence time differs from their peers in  significant ways. The choice for exclusion of those 
with less than 30 days of abstinence was to ensure that any symptoms reported (particularly of 
attention or executive functioning deficits) represented true symptomology rather than effects of 
the substances themselves. By allowing patients who abused various substances to enroll, we 
broadened our sample but may have introduced variation due to drug of choice.  
One specific limitation to this study was the failure to adequately ask about history of 
stimulant medication. Based on the questions, we were unable to tease out participants who had 
been prescribed stimulants in the past, and those who currently had prescriptions for stimulant 
medications and were taking these medications regularly. This will be an important factor to 
consider in future research to determine if ADHD had been diagnosed in childhood and a 
stimulant medication had been prescribed, but never taken, compared to those who were 
appropriately taking medication for their ADHD symptoms, due to the impact this could have on 
their ability to succeed in treatment.  
Because this was a pilot exploratory study of potential differences we conducted multiple 
statistical tests without adjusting alpha levels and so some of the significant differences might be 
due to chance sampling and these findings will need to be replicated. The self-report nature of 
the instruments could also be considered a limitation. However, all measures were chosen to 
have good psychometric properties, and in the case of executive functioning may have more 
sensitivity in capturing difficulties in everyday life (Barkley & Murphy, 2011). Despite 
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limitations in sample size and measures, the present study was successful in distinguishing a 
comorbid ADHD subgroup of substance abuse patients who likely have special treatment needs. 
Clinical Implications (Including Prevention) 
The increased risk for children and adolescents with ADHD to develop substance abuse 
is significant in terms of both prevention and clinical practice. Due to the literature suggesting 
that earlier age of initial use of alcohol is associated with poorer outcomes, it is important to 
assess and intervene earlier with ADHD youth, to prevent those with ADHD symptoms from 
turning to alcohol or other drugs to manage their symptoms. According to Wilens (2004a), 
intervening at an earlier stage in the expression of ADHD symptoms, could lead to better long-
term outcomes for co-occurring mental health and substance abuse disorders. Based on the 
interviews of those with comorbid ADHD and substance use disorders currently seeking 
treatment, it is harder to receive treatment for ADHD symptoms once there is a history of 
substance abuse. Physicians are less willing to prescribe a stimulant medication that has a high 
risk for abuse, when the patient has already demonstrated behaviors of abuse.  
Thus, several factors are important for prevention and earlier intervention. First, it would 
be important to engage in psychoeducation about ADHD symptomatology with those who are 
diagnosed during childhood and adolescence, so that they understand the symptoms of ADHD 
and how they affect them, and the importance of interventions such as medication and coping 
strategies. Thus, they will be less likely to turn to substances to mask their symptoms, rather than 
manage their symptoms through more effective methods. Second, it is clear that screening for 
ADHD needs to be integrated as a more routine part of the intake process for substance use 
treatment. Many of the participants who participated had struggled with ADHD symptoms for 
their entire life, but probably did not understand the “at risk” implications of a childhood 
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diagnosis. Because the prevalence of ADHD is unusually high within substance abuse treatment 
facilities, there is a need to screen and identify those with these symptoms, so that the symptoms 
can be properly addressed and not undermine their efforts at recovery.  
Within substance use treatment, there are several things that might help those with 
comorbid ADHD to be more successful. It is clear from the present study that those with ADHD 
in addition to substance use disorders struggle more with executive functioning deficits more 
than those with substance use disorders alone. Based on interviews with participants, it appears 
that these difficulties with executive functioning manifest in multiple ways that have 
implications on their ability to commit and ultimately be successful in treatment. Frequently 
there are specialty groups within substance use treatment centers for comorbid disorders. The 
addition of a group addressing psychoeducation about ADHD in general, and management of 
executive functioning symptoms should be beneficial for those struggling with ADHD 
symptoms. In recent years, there have been CBT evidence-based treatments developed for use 
with adult ADHD patients, such as Solantos manual specifically geared towards executive 
functioning deficits within an adult ADHD population (Solanto, 2011). To our knowledge, these 
CBT treatments have not been used with an ADHD population within a substance use treatment 
facility. However, these treatment protocols might be beneficial to adapt to a substance use 
population, in order to address the deficits in executive functioning found in those with comorbid 
ADHD and substance use. In addition, therapists’ awareness of limits of concentration and 
attention spans within treatment groups emerged as an important issue, as it allowed them to 
structure sessions or groups in a way to maximize the concentration of the participants through 
more frequent breaks, or changing activities when they sense participants attention is wandering. 
Finally, participants noted that while they are building internal motivators to succeed in 
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treatment, it is sometimes helpful to have external motivators to help keep them from relapsing. 
These would obviously need to be created on a facility and even individual level in order to be 
most successful, but may include contingency management based rewards for behaviors such as 
timeliness, attending groups, and “clean” drug screenings.  Contingency management for 
substance use is an established treatment in substance treatment centers (Stitzer & Petry, 2006) 
that seems particularly relevant for this sub-population struggling with ADHD in addition to 
their substance use.   
In conclusion, since there appears to be important differences between those with ADHD 
and those with substance use disorders alone, it is important to address these concerns in multiple 
ways—through prevention, early detection and intervention, and through considering the 
development of specialized treatments that target managing ADHD symptoms in addition to 
substance use.  
Future Research Directions  
Based on the higher prevalence rates of ADHD within substance use treatment centers, 
we sought to extend the literature in this area and move beyond a prevalence study to begin to 
describe the differences between these two groups. Our research found several clear and highly 
important differences between these two groups, but future research will need to corroborate and 
extend these findings. While we selected three domains (i.e., substance use patterns, motives for 
use, and executive functioning) that might have had important differences between these two 
groups, and particularly might have implications for treatment, these are by no means the only 
potential differences between these two groups. Future research would do well to continue to 
refine these differences and uncover other differences between the groups (e.g., reward 
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sensitivity) that could have important implications in helping those with comorbid ADHD and 
substance use disorder be successful in recovery efforts.    
One area we addressed in order to control for the possible effects was that of conduct 
disorder. The literature in this area is conflicted on the specific roles and pathways of ADHD, 
conduct disorder, substance use disorders.  Future research is needed to disentangle this highly 
complex area, as the specific roles each play will be important in future research and designing 
prevention interventions.  
 A number of prior studies reviewed in Table 1 have examined differences in substance 
abuse history associated with comorbid ADHD but most of this research has been conducted in 
conjunction with prevalence studies. As a result, different substances of abuse and populations 
enrolled in different treatments programs have been used, and findings have not always been 
consistent. Although the present study extends this literature, it will be important to more 
systematically address differences related to substance use variables, and determine which have 
the most implication in terms of their future effects. Specifically, based on our findings, future 
researchers may want to include age of initiation of nicotine and marijuana in addition to age of 
initiation of alcohol in future analyses. Researchers may also want to address the specific types 
of substances those with ADHD are utilizing, as although stimulant use was one predictor of 
differences between the groups, it was not reported as the primary drug of choice for any the 
ADHD group members.  
The present study also has research implications for studying motives for use. The self-
medication hypothesis for ADHD has traditionally assumed that those with ADHD would use 
stimulants to manage their ADHD symptoms. However, our results suggest that our participants 
may choose a variety of drugs, including opiates, to manage or escape their symptoms. Further, 
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aside from the discussion of self-medication in the comorbid ADHD and substance abuse 
literature, the author could not find any studies empirically examining other motives for drinking 
or substance use within an ADHD population. It is clear that more research needs to be 
conducted in this area, specifically looking at coping motives, and different substances beyond 
stimulants, including opioids. Although the results between the two groups for motives for using 
alcohol were not significant, it is important to continue studies in this area given our small and 
particular sample. Studying motives for drug use with an ADHD population and changes in 
motives over time continues to be an important area for future research, particularly given that 
those with ADHD tend to use a greater variety of substances than their counterparts without 
ADHD symptoms. Understanding their expectancies for using more and varied substances may 
be an important factor that could have significant implications in terms of treatment.  
Finally, more robust, longitudinal research is needed into executive functioning among 
ADHD individuals and the relationship of executive functioning to substance use. Such research 
might determine the degree to which specific executive functioning deficits (e.g., impulsivity or 
response inhibition) are predictive of developing substance use problems (Giancola & Tarter, 
1999) and also which areas of executive functioning might be exacerbated by patient substance 
use. Future research should also include some performance based measures of executive 
functioning, as they can be helpful in determining specific deficits in executive functioning 
(Kamradt, Ullsperger, & Nikolas, 2014). As Kamradt discussed, more research is needed that 
concurrently looks at both types of executive functioning measures—self-report assessments and 
performance based measures. This would  not only add to our understanding of the symptoms 
and impairments of those with ADHD (Kamradt et al., 2014) but also could add to our 
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knowledge around the differences between those with ADHD and substance use disorders versus 
those with  substance use disorders alone.  
Based on the highly significant differences found not only between our comorbid group and 
substance use only group, but also Barkley’s ADHD group, it is clear that future research studies 
should explore the differences between those with comorbid ADHD and substance use, 
substance use alone, and ADHD alone in terms of their executive functioning deficits. 
Prospective research might clarify how such deficits and possible moderator variables affect 
important life outcomes including substance use. Lastly, as discussed above, applied research on 
how targeting such deficits in comorbid ADHD patients with substance abuse difficulties might 
enhance treatment is also need.
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East Carolina University 
 
 
 
Informed Consent to Participate in Research 
Information to consider before taking part in research that has no 
more than minimal risk. 
 
 
Title of Research Study: Co-occurring ADHD and Substance Abuse: Substance Use Patterns, Motives and 
Executive Functioning  
Principal Investigator: Marina Stanton, MS 
Institution/Department or Division: East Carolina University Psychology Department  
Address: 312 RAWL Building, Greenville, NC 27858  
Telephone #: 252-737-4180 
 
Study Sponsor/Funding Source: ECU Psychological Assessment and Specialty Services Clinic  
 
Researchers within East Carolina University (ECU) psychology department study problems in society, 
health issues including substance abuse, behavior problems and the human condition.  Our goal is to try to 
find ways to improve the lives of individuals who may have behavioral health challenges.  To do this, we 
need the help of volunteers who are willing to take part in research. We are partnering with PORT Human 
Services because they are the main provider of substance abuse services in the region.  
 
Why is this research being done? 
The purpose of this research is to better describe any differences or needs of people with attention 
difficulties vs. those who do not, within a treatment center for substance use disorders. The decision to 
take part in this research is yours to make.  By conducting this research, we hope to learn if there are 
differences between those who struggle with comorbid attentional difficulties in terms of patterns of use 
(including substances used and treatment history), motives for use, and ability to plan, prioritize, and 
pursue goals.  
 
Why am I being invited to take part in this research? 
You are being invited to take part in this research because you are a young adult (between 18-35 years of 
age), and receiving help for substance use problems at PORT Human services. If you volunteer to take 
part in this research, you will be one of about 40 people to do so.  
 
Are there reasons I should not take part in this research?  
You understand that you should not volunteer for this study if you are under 18 years of age, or older than 
35 years of age, or have a history of a Traumatic Brain Injury. In addition, you understand that you should 
not volunteer for this study if you have used alcohol or other drugs in the past 30 days, or are 
experiencing any withdrawal symptoms because these might influence the measures used in this study.  
 
What other choices do I have if I do not take part in this research? 
You can choose not to participate. This decision will not affect the services you are already receiving at 
PORT Human Services in any way, either now or in the future, nor will they affect in any way any future 
interest in ECU. 
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Where is the research going to take place and how long will it last? 
The research procedures will be conducted at PORT Human Services outpatient clinic, and will consist of 
one research session.  The total amount of time you will be asked to volunteer for this study is one session 
estimated to last between sixty minutes to one and a half hours (estimated time to be 60 minutes). 
What will I be asked to do? 
You are being asked to do the following: You will complete pre-screening questionnaires regarding 
difficulties with attention during childhood, and over the past 6 months. This measure should take 
between 3-7 minutes to complete. Based on the results of your pre-screening and our current study 
sample, you may be invited to continue with the research whether or not you have difficulties with 
attention.  
 
If you are invited to continue with the research, you will be asked to fill out additional questionnaires and 
interviews, which are expected to take approximately one hour. 
 
Interviews: 
A trained research team member will ask you questions about your substance use and treatment history. 
In addition, you may be asked questions about possible attentional difficulties, and how these influence 
your use of alcohol and/or other drugs, or your efforts at recovery.  
 
Questionnaires:  
Along with, and embedded within the interview, you will be asked to fill out several questionnaires that 
ask you to report on demographics, including any difficulties you had with conduct problems in 
childhood/ adolescence, desired effects you have wanted from drinking or use of other drugs, and 
problems you may have with time management, motivation, self-organization, self-restraint and 
regulation of emotions.  
 
What possible harms or discomforts might I experience if I take part in the research? 
While we believe that this is a minimal risk of harm study, there are always some risks (the chance of 
harm) when taking part in any research. Discussing psychosocial and/or health related topics, including 
alcohol and or other drug use, may be distressing for you. In order to try and minimize any potential risks, 
you do not have to answer any question you do not wish to answer, and most participants actually benefit 
from telling their story to a concerned listener who is encouraging them in their efforts toward recovery. 
If you become distressed during the course of the study, we will stop the study assessment immediately. 
Further, we will seek information about whether you could benefit from additional support from your 
clinician or psychiatrist at PORT Human Services. We will determine who may be the best/most 
immediate person at PORT to follow-up with you in order to reduce any distress and eliminate any risk of 
harm.   
 
Your participation and the interview/ questionnaire data you provide will be considered confidential. 
There is one exception or limit to confidentiality, if you disclose abuse or neglect of a child or vulnerable 
adult, or verbalize an immediate risk of harm to self or others, we are mandated to report this, but will 
discuss this with you before moving forward with reporting.  
 
What are the possible benefits I may experience from taking part in this research? 
We believe that there are both direct and indirect benefits of participating in the present study. With 
regard to direct benefits, people often report talking about their recovery and factors that make abstinence 
a challenge is beneficial for people. With regard to indirect benefits, this research might help us learn 
more about how to help those with attentional difficulties be more successful in their efforts at recovery 
from substance use disorders. Moreover, after the study has been completed, general study aggregated 
results will be shared with staff at PORT Human services in order to help them understand the needs of 
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patients with attention difficulties, and any possible interventions that could be helpful to their treatment. 
Finally, a 1-page summary of the findings of the study will be made available at PORT Human services to 
all patients or staff at PORT interested in these results.    
 
 
 
Will I be paid for taking part in this research? 
If you are selected to participate after the prescreening questionnaire is completed, you will be given a 
small token of appreciation for the time you volunteered. All participants who complete the interview and 
questionnaires will receive a $10 Walmart gift card, regardless of your completion of these measures.    
 
What will it cost me to take part in this research?  
It will not cost you any money to be part of the research, although you are donating your time.   
 
Who will know that I took part in this research and learn personal information about me? 
To do this research, ECU and the people and organizations listed below may know that you took part in this 
research and may see information about you that is normally kept private.  With your permission, these 
people may use your private information to do this research: 
• ECU Psychology research team 
• Port Human Services staff members, who will either tell you about the opportunity, or who have 
responsibility for overseeing your welfare during this research should you become distressed. In 
addition, a copy of this informed consent will be provided to PORT, and placed in your file. PORT 
staff will NOT be informed of any other information about you, unless you specifically request 
information to be reported to your counselor. The only instances that we would have a duty to 
report (limit to confidentiality above) if you were to disclose information that puts either you or 
others at potential risk.  
• Any agency of the federal, state, or local government that regulates human research.  This includes 
the Department of Health and Human Services (DHHS), the North Carolina Department of Health, 
and the Office for Human Research Protections. 
• The University & Medical Center Institutional Review Board (UMCIRB) and its staff, who have 
responsibility for overseeing your welfare during this research, and other ECU staff who oversee 
this research. 
 
How will you keep the information you collect about me secure?  How long will you keep it? 
Any information that is obtained in connection with this study will remain confidential, and will only be 
known to the study investigators, and will be disclosed only with your permission. The only place your 
name will appear is on this informed consent and on the individual page of the $10 gift card log kept by 
the researchers; otherwise a numerical code will be used. No names or other personally identifying 
information will be included in any analysis or reports that result from this study. All data files and 
questionnaires will be kept securely locked within the ECU psychology department lab and will be 
destroyed seven years following the study. An electronic database with all participants’ information will 
be kept confidential on a secure Pirate Drive, but will not contain any identifiable information other than a 
pre-determined participation identification number.  
 
What if I decide I do not want to continue in this research? 
If you decide you no longer want to be in this research after it has already started, you may stop at any 
time.  You will not be penalized or criticized for stopping.  If you have already completed the pre-screen 
and started with additional questionnaires or interviews, you will not lose any benefits that you should 
normally receive.  
 
 120 
 
Who should I contact if I have questions? 
The people conducting this study will be available to answer any questions concerning this research, now 
or in the future.  You may contact the Principal Investigator, Mrs. Marina Stanton, at 252-702-5044 (days, 
between 9:00-5:00), or the Faculty Supervisor, Dr. Tony Cellucci, at 252-737-4180 (days between 10:00-
5:00).    
 
If you have questions about your rights as someone taking part in research, you may call the Office for 
Human Research Integrity (OHRI) at phone number 252-744-2914 (days, 8:00 am-5:00 pm).  If you 
would like to report a complaint or concern about this research study, you may call the Director of the 
OHRI, at 252-744-1971. 
I have decided I want to take part in this research.  What should I do now? 
The person obtaining informed consent will ask you to read the following and if you agree, you should 
sign this form:   
 
• I have read (or had read to me) all of the above information.   
• I have had an opportunity to ask questions about things in this research I did not understand and 
have received satisfactory answers.   
• I know that I can stop taking part in this study at any time.   
• By signing this informed consent form, I am not giving up any of my rights.   
• I have been given a copy of this consent document, and it is mine to keep.  
 
 
          _____________ 
Participant's Name  (PRINT)                                 Signature                            Date   
 
 
Person Obtaining Informed Consent:  I have conducted the initial informed consent process.  I have 
orally reviewed the contents of the consent document with the person who has signed above, and 
answered all of the person’s questions about the research. 
 
             
Person Obtaining Consent (PRINT)                      Signature                                    Date   
 
 
             
Principal Investigator   (PRINT)                           Signature                                    Date   
(If other than person obtaining informed consent) 
 
 
 
 
 
 
  
 
APPENDIX B: MEASURES 
Demographics 
1. Age:_____  
2. Gender:_____________  
3. What is your current marital/romantic relationship status?  
____Single        ____Separated   
____Married     ____Divorced     
____Widowed  ____Cohabitating  
 
3a. If single, are you currently in a relationship?  
____Yes, dating a single person exclusively (boyfriend/girlfriend) 
____Yes, dating multiple people 
____No 
 
4. Ethnicity: (check only one) 
____African American   ____Caucasian/ European American 
____Asian American  ____Native American 
____Hispanic American ____Other: _______________ 
____Multiracial:_________________ 
 
5. How many years of education have you completed? _______ 
 
6. What is the highest level of education you have completed? 
___ Less than 4th grade ___ High school graduate (or GED) 
___ 5th-8th grade   ___ Some college (no degree) 
___ 9th grade   ___ Associates degree (2 years) 
___10th grade   ___ Bachelor’s degree 
___ 11th grade   ___ Graduate degree  
___ Training or technical education:_______________________ 
 
7. Have you ever repeated a grade, or been held back? ____ Yes               _____No 
If yes, how many times, and for what grade(s)? 
_________________________________________________ 
8. Were you ever been suspended or expelled from school? _____ Yes     ______No  
 
 122 
 
9. What is your current employment status? (Mark all that apply) 
___ Full time (35+ hours)    ____ Unpaid service/volunteer   
___ Part time (regular hours)    ____ Retired/disability 
___ Part time (irregular hours)  ____Unemployed 
_____Other:_________________________ 
 
10. What is your current education status?  
___ Part time student       ___ Full time student (9+ credit hours)   
___ Not currently attending school   
 
11. What has been your usual employment status over the past three years? (Mark all that apply) 
___ Full time (35+ hours)     ____ Unpaid service/volunteer   
___ Part time (regular hours)     ____ Retired/disability 
___ Part time (irregular hours)   ____ Unemployed   
___Other:_________________________ 
 
12. What has been your usual education status over the past three years?  
___ Part time student       ____ Full time student (9+ credit hours) 
___ Not applicable    
 
13. How many jobs have you held over the past three years? __________ 
 
14. Have you ever been diagnosed with a traumatic brain injury? ____Yes  _____No 
 
15. Have you ever been diagnosed with a mood or attention disorder (such as Depression, 
Anxiety, or ADHD/ADD)?  ____Yes ____No 
If you checked Yes to the question above, what was (were) your diagnosis(es)? 
______________________________________________________________ 
 
16. Have you ever taken medication for a mood or attention disorder? 
____Yes ____No 
If you checked Yes to the question above, what medication(s) did you take? 
______________________________________________________________ 
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Treatment history: 
1)  How old were you the first time you ever sought professional help (including Alcoholics 
Anonymous/Narcotics Anonymous) for help with your drinking or other drug use?        
AGE ______ 
 
2) How many times in your life have you been treated for alcohol or other drug use? (Include 
separate treatment episodes including current treatment) (Include detoxification, halfway houses, 
in/outpatient counseling, and AA or NA (if 3+ meetings within one month period): 
a) Alcohol abuse? _______ 
b) Drug abuse? _________ 
 
3) How many of these were detox only: 
a) Alcohol? __________ 
b) Drugs? ___________ 
 
4) Were you ever mandated to seek treatment by a court or probation?   Y/N  Number of 
times________ 
 
5) What is the longest period of time (e.g., days or months), you have stayed enrolled/ active in a 
treatment program? ____________ 
 
6) What is the longest time period since started drinking you were completely abstinent in your 
life (approximately) (e.g., X days, months, or year(s)? ________________ 
 
7) What is the longest time period since started using other drugs you were completely drug-free 
(abstinent) in your life (approximately) (e.g., X days, months, or year(s)? ________________ 
 
8) Within the past 6 months (180 days), How long have you been completely abstinent from 
using alcohol?  (approximately)____________________ 
 
9) Within the past 6 months (180 days), How long have you been completely abstinent from 
using any drugs (besides alcohol)?  (approximately)____________________ 
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Qualitative Questions for Co-occurring ADHD and Substance Abuse Group: 
Prior to ending, I would like to ask you a couple of open-ended questions and give you an opportunity to 
say anything you want to add to this research.  
1. We have been talking about your problems with attention and possible ADHD through your life. 
How do you think your difficulties with attention have influenced you use of alcohol and/or other 
drugs? 
 
 
2. Do you think your drinking (or any other drug use) improved, worsened, or had no impact on 
your ADHD symptoms? Explain 
 
 
 
 
3. How do you think your difficulties with attention have influenced your efforts at recovery from 
alcohol and other drugs?    
 
 
4. We are interested in making recommendations to help people with ADHD who are in treatment 
for substance use disorders. In what ways do you think your difficulties with attention have 
affected your progress in substance abuse treatment and getting the most out of the treatment?    
 
 
 
 
5. How could alcohol and/or other drug treatment better help individuals with co-occurring attention 
problems?   
 
 
 
6. Any additional comments or ideas?  
 
 
